Staphylococcal	B-protein
enterotoxins	I-protein
modulate	O
interleukin	B-protein
2	I-protein
receptor	I-protein
expression	O
and	O
ligand-induced	O
tyrosine	O
phosphorylation	O
of	O
the	O
Janus	B-protein
protein-tyrosine	I-protein
kinase	I-protein
3	I-protein
(	O
Jak3	B-protein
)	O
and	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
(	O
Stat	B-protein
proteins	I-protein
)	O
.	O

Staphylococcal	B-protein
enterotoxins	I-protein
(	O
SE	B-protein
)	O
stimulate	O
T	B-cell_type
cells	I-cell_type
expressing	O
the	O
appropriate	O
variable	B-protein
region	I-protein
beta	I-protein
chain	I-protein
of	I-protein
(	I-protein
V	I-protein
beta	I-protein
)	I-protein
T-cell	I-protein
receptors	I-protein
and	O
have	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
several	O
autoimmune	O
diseases	O
.	O

Depending	O
on	O
costimulatory	O
signals	O
,	O
SE	B-protein
induce	O
either	O
proliferation	O
or	O
anergy	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

In	O
addition	O
,	O
SE	B-protein
can	O
induce	O
an	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
nonresponsive	O
state	O
and	O
apoptosis	O
.	O

Here	O
,	O
we	O
show	O
that	O
SE	B-protein
induce	O
dynamic	O
changes	O
in	O
the	O
expression	O
of	O
and	O
signal	O
transduction	O
through	O
the	O
IL-2	B-protein
receptor	I-protein
(	I-protein
IL-2R	I-protein
)	I-protein
beta	I-protein
and	I-protein
gamma	I-protein
chains	I-protein
(	O
IL-2R	B-protein
beta	I-protein
and	O
IL-2R	B-protein
gamma	I-protein
)	O
in	O
human	B-cell_line
antigen-specific	I-cell_line
CD4+	I-cell_line
T-cell	I-cell_line
lines	I-cell_line
.	O

Thus	O
,	O
after	O
4	O
hr	O
of	O
exposure	O
to	O
SEA	B-protein
and	O
SEB	B-protein
,	O
the	O
expression	O
of	O
IL-2R	B-protein
beta	I-protein
was	O
down-regulated	O
,	O
IL-2R	B-protein
gamma	I-protein
was	O
slightly	O
up-regulated	O
,	O
while	O
IL-2R	B-protein
alpha	I-protein
remained	O
largely	O
unaffected	O
.	O

The	O
changes	O
in	O
the	O
composition	O
of	O
IL-2Rs	B-protein
were	O
accompanied	O
by	O
inhibition	O
of	O
IL-2	B-protein
-induced	O
tyrosine	O
phosphorylation	O
of	O
the	O
Janus	B-protein
protein-tyrosine	I-protein
kinase	I-protein
3	I-protein
(	O
Jak3	B-protein
)	O
and	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
called	O
Stat3	B-protein
and	O
Stat5	B-protein
.	O

In	O
parallel	O
experiments	O
,	O
IL-2	B-protein
-driven	O
proliferation	O
was	O
inhibited	O
significantly	O
.	O

After	O
16	O
hr	O
of	O
exposure	O
to	O
SE	B-protein
,	O
the	O
expression	O
of	O
IL-2R	B-protein
beta	I-protein
remained	O
low	O
,	O
while	O
that	O
of	O
IL2R	B-protein
alpha	I-protein
and	O
IL2R	B-protein
gamma	I-protein
was	O
further	O
up-regulated	O
,	O
and	O
ligand-induced	O
tyrosine	O
phosphorylation	O
of	O
Jak3	B-protein
and	O
Stat	B-protein
proteins	I-protein
was	O
partly	O
normalized	O
.	O

Yet	O
,	O
IL-2	B-protein
-driven	O
proliferation	O
remained	O
profoundly	O
inhibited	O
,	O
suggesting	O
that	O
signaling	O
events	O
other	O
than	O
Jak3	B-protein
/Stat	B-protein
activation	O
had	O
also	O
been	O
changed	O
following	O
SE	B-protein
stimulation	O
.	O

In	O
conclusion	O
,	O
our	O
data	O
suggest	O
that	O
SE	B-protein
can	O
modulate	O
IL-2R	B-protein
expression	O
and	O
signal	O
transduction	O
involving	O
the	O
Jak/Stat	B-protein
pathway	O
in	O
CD4+	B-cell_line
T-cell	I-cell_line
lines	I-cell_line
.	O

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
Vol	NULL
.	NULL

92	NULL
,	NULL
Pp	NULL
.	NULL

10995-10999	NULL
,	NULL
November	NULL
1995	NULL
Immunology	NULL
Staphylococcal	NULL
enterotoxins	NULL
modulate	NULL
interleukin	NULL
2	NULL
receptor	NULL
expression	NULL
and	NULL
ligand-induced	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
the	NULL
Janus	NULL
protein-tyrosine	NULL
kinase	NULL
3	NULL
(	NULL
Jak3	NULL
)	NULL
and	NULL
signal	NULL
transducers	NULL
and	NULL
activators	NULL
of	NULL
transcription	NULL
(	NULL
Stat	NULL
proteins	NULL
)	NULL
METTE	NULL
NiELsEN*T	NULL
,	NULL
ArnE	NULL
SyvEIGAaARDt	NULL
,	NULL
CaRsTEN	NULL
ROopKES	NULL
,	NULL
METTE	NULL
NoRrDpAHL*	NULL
,	NULL
AnD	NULL
NieELs	NULL
Opum*	NULL
*Cell	NULL
Cybernetics	NULL
Laboratory	NULL
,	NULL
Institute	NULL
of	NULL
Medical	NULL
Microbiology	NULL
and	NULL
Immunology	NULL
22.5	NULL
,	NULL
and	NULL
$	NULL
Institute	NULL
of	NULL
Medical	NULL
Anatomy	NULL
,	NULL
University	NULL
of	NULL
Copenhagen	NULL
,	NULL
The	NULL
Panum	NULL
Institute	NULL
,	NULL
Blegdamsvej	NULL
3¢	NULL
,	NULL
2200	NULL
Copenhagen	NULL
N	NULL
,	NULL
Denmark	NULL
;	NULL
and	NULL
*Tissue	NULL
Typing	NULL
Laboratory	NULL
,	NULL
State	NULL
University	NULL
Hospital	NULL
of	NULL
Copenhagen	NULL
,	NULL
2200	NULL
Copenhagen	NULL
N	NULL
,	NULL
Denmark	NULL
Communicated	NULL
by	NULL
Hans	NULL
Ussing	NULL
,	NULL
University	NULL
of	NULL
Copenhagen	NULL
,	NULL
Copenhagen	NULL
,	NULL
Denmark	NULL
,	NULL
August	NULL
2	NULL
,	NULL
1995	NULL
ABSTRACT	NULL
Staphylococcal	NULL
enterotoxins	NULL
(	NULL
SE	NULL
)	NULL
stimulate	NULL
T	NULL
cells	NULL
expressing	NULL
the	NULL
appropriate	NULL
variable	NULL
region	NULL
B	NULL
chain	NULL
of	NULL
(	NULL
Ve	NULL
)	NULL
T-cell	NULL
receptors	NULL
and	NULL
have	NULL
been	NULL
implicated	NULL
in	NULL
the	NULL
pathogenesis	NULL
of	NULL
several	NULL
autoimmune	NULL
diseases	NULL
.	NULL

Depending	NULL
on	NULL
costimulatory	NULL
signals	NULL
,	NULL
SE	NULL
induce	NULL
either	NULL
proliferation	NULL
or	NULL
anergy	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
SE	NULL
can	NULL
induce	NULL
an	NULL
interleukin-2	NULL
(	NULL
IL-2	NULL
)	NULL
nonresponsive	NULL
state	NULL
and	NULL
apoptosis	NULL
.	NULL

Here	NULL
,	NULL
we	NULL
show	NULL
that	NULL
SE	NULL
induce	NULL
dynamic	NULL
changes	NULL
in	NULL
the	NULL
expression	NULL
of	NULL
and	NULL
signal	NULL
transduction	NULL
through	NULL
the	NULL
IL-2	NULL
receptor	NULL
(	NULL
IL-2R	NULL
)	NULL
B	NULL
and	NULL
y	NULL
chains	NULL
(	NULL
IL-2R	NULL
$	NULL
and	NULL
IL-2Ry	NULL
)	NULL
in	NULL
human	NULL
antigen-specific	NULL
CD4*	NULL
T-cell	NULL
lines	NULL
.	NULL

Thus	NULL
,	NULL
after	NULL
4	NULL
hr	NULL
of	NULL
exposure	NULL
to	NULL
SEA	NULL
and	NULL
SEB	NULL
,	NULL
the	NULL
expression	NULL
of	NULL
IL-2R	NULL
$	NULL
B	NULL
was	NULL
down-regulated	NULL
,	NULL
IL-2Ry	NULL
was	NULL
slightly	NULL
up-regulated	NULL
,	NULL
while	NULL
IL-2Ra	NULL
remained	NULL
largely	NULL
unaffected	NULL
.	NULL

The	NULL
changes	NULL
in	NULL
the	NULL
composition	NULL
of	NULL
IL-2Rs	NULL
were	NULL
accompanied	NULL
by	NULL
inhibition	NULL
of	NULL
IL-2-induced	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
the	NULL
Janus	NULL
protein-tyrosine	NULL
kinase	NULL
3	NULL
(	NULL
Jak3	NULL
)	NULL
and	NULL
signal	NULL
transducers	NULL
and	NULL
activators	NULL
of	NULL
transcription	NULL
called	NULL
Stat3	NULL
and	NULL
Stat5	NULL
.	NULL

In	NULL
parallel	NULL
experiments	NULL
,	NULL
IL-2-driven	NULL
proliferation	NULL
was	NULL
inhibited	NULL
significantly	NULL
.	NULL

After	NULL
16	NULL
hr	NULL
of	NULL
exposure	NULL
to	NULL
SE	NULL
,	NULL
the	NULL
expression	NULL
of	NULL
IL-2RB	NULL
remained	NULL
low	NULL
,	NULL
while	NULL
that	NULL
of	NULL
IL2Ra	NULL
and	NULL
IL2Ry	NULL
was	NULL
further	NULL
up-regulated	NULL
,	NULL
and	NULL
ligand-induced	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
Jak3	NULL
and	NULL
Stat	NULL
proteins	NULL
was	NULL
partly	NULL
normalized	NULL
.	NULL

Yet	NULL
,	NULL
IL-2-driven	NULL
proliferation	NULL
remained	NULL
profoundly	NULL
inhibited	NULL
,	NULL
suggesting	NULL
that	NULL
signaling	NULL
events	NULL
other	NULL
than	NULL
Jak3/Stat	NULL
activation	NULL
had	NULL
also	NULL
been	NULL
changed	NULL
following	NULL
SE	NULL
stimulation	NULL
.	NULL

In	NULL
conclu-sion	NULL
,	NULL
our	NULL
data	NULL
suggest	NULL
that	NULL
SE	NULL
can	NULL
modulate	NULL
IL-2R	NULL
expression	NULL
and	NULL
signal	NULL
transduction	NULL
involving	NULL
the	NULL
Jak/Stat	NULL
pathway	NULL
in	NULL
CD4*	NULL
T-cell	NULL
lines	NULL
.	NULL

The	NULL
exotoxins	NULL
produced	NULL
by	NULL
Staphylococcus	NULL
aureus	NULL
cause	NULL
toxic	NULL
shock-like	NULL
syndromes	NULL
and	NULL
have	NULL
been	NULL
implicated	NULL
in	NULL
the	NULL
pathogenesis	NULL
of	NULL
various	NULL
allergic	NULL
and	NULL
autoimmune	NULL
diseases	NULL
(	NULL
reviewed	NULL
in	NULL
ref	NULL
.	NULL

1	NULL
)	NULL
.	NULL

Staphylococcus	NULL
enterotoxins	NULL
(	NULL
SE	NULL
)	NULL
are	NULL
among	NULL
the	NULL
most	NULL
potent	NULL
mitogens	NULL
for	NULL
T	NULL
lymphocytes	NULL
(	NULL
2	NULL
,	NULL
3	NULL
)	NULL
and	NULL
often	NULL
are	NULL
referred	NULL
to	NULL
as	NULL
bacterial	NULL
superantigens	NULL
.	NULL

SE	NULL
bind	NULL
with	NULL
high	NULL
affinities	NULL
to	NULL
major	NULL
histocompatibility	NULL
complex	NULL
(	NULL
MHC	NULL
)	NULL
class	NULL
II	NULL
molecules	NULL
on	NULL
antigen-presenting	NULL
cells	NULL
(	NULL
APC	NULL
)	NULL
and	NULL
interact	NULL
with	NULL
T	NULL
cells	NULL
bearing	NULL
certain	NULL
T-cell	NULL
receptor	NULL
(	NULL
TCR	NULL
)	NULL
variable	NULL
region	NULL
B	NULL
chains	NULL
(	NULL
V	NULL
;	NULL
chains	NULL
)	NULL
(	NULL
4-6	NULL
)	NULL
.	NULL

SE	NULL
can	NULL
induce	NULL
early	NULL
activation	NULL
signals	NULL
,	NULL
cytokine	NULL
production	NULL
,	NULL
and	NULL
proliferation	NULL
of	NULL
T	NULL
cells	NULL
expressing	NULL
the	NULL
appropriate	NULL
TCR	NULL
V	NULL
;	NULL
chains	NULL
(	NULL
3	NULL
,	NULL
7-9	NULL
)	NULL
.	NULL

Addition-ally	NULL
,	NULL
SE	NULL
are	NULL
able	NULL
to	NULL
induce	NULL
anergy	NULL
,	NULL
nonresponsiveness	NULL
to	NULL
interleukin	NULL
2	NULL
(	NULL
IL-2	NULL
)	NULL
,	NULL
and	NULL
programmed	NULL
cell	NULL
death	NULL
(	NULL
apoptosis	NULL
)	NULL
in	NULL
vivo	NULL
and	NULL
in	NULL
vitro	NULL
(	NULL
10-16	NULL
)	NULL
.	NULL

Costimulatory	NULL
signals	NULL
delivered	NULL
through	NULL
B7/CD28	NULL
and/or	NULL
lymphocyte	NULL
function-associated	NULL
antigen	NULL
1/intercellular	NULL
cell	NULL
adhesion	NULL
molecule	NULL
(	NULL
LFA-1/ICAM	NULL
)	NULL
play	NULL
a	NULL
critical	NULL
role	NULL
in	NULL
determining	NULL
the	NULL
outcome	NULL
of	NULL
T-cell	NULL
stimulation	NULL
with	NULL
SE	NULL
(	NULL
5	NULL
,	NULL
12	NULL
,	NULL
17-19	NULL
)	NULL
.	NULL

Recent	NULL
data	NULL
provide	NULL
The	NULL
publication	NULL
costs	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
page	NULL
charge	NULL
payment	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

§1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

10995	NULL
evidence	NULL
of	NULL
an	NULL
early	NULL
signaling	NULL
defect	NULL
in	NULL
anergized	NULL
T	NULL
cells	NULL
following	NULL
TCR	NULL
stimulation	NULL
with	NULL
endogeneous	NULL
superantigens	NULL
,	NULL
chemically	NULL
fixed	NULL
APC	NULL
,	NULL
or	NULL
anti-TCR/CD3	NULL
antibodies	NULL
(	NULL
20-24	NULL
)	NULL
.	NULL

However	NULL
,	NULL
it	NULL
is	NULL
still	NULL
largely	NULL
unknown	NULL
how	NULL
exposure	NULL
to	NULL
SE	NULL
induces	NULL
IL-2	NULL
nonresponsiveness	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

The	NULL
high-affinity	NULL
IL-2R	NULL
is	NULL
composed	NULL
of	NULL
three	NULL
distinct	NULL
chains	NULL
(	NULL
a	NULL
,	NULL
B	NULL
,	NULL
and	NULL
y	NULL
)	NULL
of	NULL
which	NULL
the	NULL
B	NULL
and	NULL
y	NULL
chains	NULL
are	NULL
essential	NULL
for	NULL
efficient	NULL
signal	NULL
transduction	NULL
because	NULL
of	NULL
their	NULL
physical	NULL
association	NULL
with	NULL
intracellular	NULL
kinases-e.g	NULL
.	NULL

,	NULL
p56	NULL
``	NULL
®	NULL
,	NULL
raf-1	NULL
,	NULL
and	NULL
the	NULL
Janus	NULL
protein	NULL
tyrosine	NULL
kinases	NULL
Jak1	NULL
and	NULL
Jak3	NULL
(	NULL
25-29	NULL
)	NULL
.	NULL

Recently	NULL
,	NULL
it	NULL
was	NULL
shown	NULL
that	NULL
the	NULL
IL-2R	NULL
is	NULL
coupled	NULL
to	NULL
the	NULL
newly	NULL
described	NULL
Jak/Stat	NULL
signaling	NULL
pathway	NULL
,	NULL
where	NULL
Stat	NULL
proteins	NULL
are	NULL
signal	NULL
transducers	NULL
and	NULL
activators	NULL
of	NULL
transcription	NULL
.	NULL

Thus	NULL
,	NULL
IL-2R	NULL
ligation	NULL
induced	NULL
tyrosine	NULL
phosphorylation	NULL
and	NULL
activation	NULL
of	NULL
Jak1	NULL
and	NULL
Jak3	NULL
and	NULL
tyrosine	NULL
phosphorylation	NULL
and	NULL
nuclear	NULL
translocation	NULL
of	NULL
Stat3	NULL
,	NULL
Stat5	NULL
,	NULL
and	NULL
other	NULL
Stat-like	NULL
proteins	NULL
(	NULL
30-33	NULL
)	NULL
.	NULL

Here	NULL
,	NULL
we	NULL
provide	NULL
evidence	NULL
that	NULL
SE	NULL
,	NULL
at	NULL
least	NULL
partly	NULL
,	NULL
mediate	NULL
their	NULL
effect	NULL
through	NULL
alterations	NULL
in	NULL
the	NULL
a-	NULL
,	NULL
B-	NULL
,	NULL
and	NULL
y-chain	NULL
composition	NULL
of	NULL
IL-2Rs	NULL
and	NULL
an	NULL
uncoupling	NULL
of	NULL
the	NULL
Jak/Stat	NULL
signaling	NULL
pathway	NULL
,	NULL
rendering	NULL
T	NULL
cells	NULL
nonresponsive	NULL
to	NULL
IL-2	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Antibodies	NULL
and	NULL
Other	NULL
Reagents	NULL
.	NULL

Anti-phosphotyrosine	NULL
monoclonal	NULL
antibody	NULL
(	NULL
mAb	NULL
)	NULL
(	NULL
4G10	NULL
)	NULL
and	NULL
Jak3	NULL
Ab	NULL
(	NULL
no	NULL
.	NULL

06-428	NULL
)	NULL
were	NULL
purchased	NULL
from	NULL
Upstate	NULL
Biotechnology	NULL
(	NULL
Lake	NULL
Placid	NULL
,	NULL
NY	NULL
)	NULL
,	NULL
and	NULL
Stat3	NULL
mAb	NULL
(	NULL
no	NULL
.	NULL

$	NULL
21320	NULL
)	NULL
and	NULL
Stat5	NULL
mAb	NULL
(	NULL
no	NULL
.	NULL

$	NULL
21520	NULL
)	NULL
were	NULL
from	NULL
Transduction	NULL
Laboratories	NULL
(	NULL
Lexington	NULL
,	NULL
KY	NULL
)	NULL
.	NULL

Antibodies	NULL
used	NULL
in	NULL
fluorescence-activated	NULL
cell	NULL
sorting	NULL
(	NULL
FACS	NULL
)	NULL
analysis	NULL
were	NULL
against	NULL
IL-2Ra	NULL
[	NULL
CD25	NULL
,	NULL
IOTI14a	NULL
,	NULL
fluorescein	NULL
isothiocyanate	NULL
(	NULL
FITC	NULL
)	NULL
-conjugated	NULL
;	NULL
Immunotech	NULL
,	NULL
France	NULL
}	NULL
,	NULL
IL-2R	NULL
$	NULL
B	NULL
[	NULL
p75	NULL
,	NULL
phycoerythrin	NULL
(	NULL
PE	NULL
)	NULL
-conjugated	NULL
;	NULL
Becton	NULL
Dickinson	NULL
,	NULL
no	NULL
.	NULL

340254	NULL
]	NULL
,	NULL
IL-2Ry	NULL
[	NULL
TUGh4	NULL
;	NULL
gift	NULL
from	NULL
K.	NULL
Sugamura	NULL
,	NULL
Tohoku	NULL
University	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
Sendai	NULL
,	NULL
Japan	NULL
(	NULL
34	NULL
)	NULL
]	NULL
,	NULL
ICAM-1	NULL
(	NULL
CD54	NULL
,	NULL
84H10	NULL
,	NULL
PE-conjugated	NULL
;	NULL
Immunotech	NULL
,	NULL
Luminy	NULL
,	NULL
France	NULL
)	NULL
,	NULL
and	NULL
secondary	NULL
goat	NULL
anti-mouse	NULL
antibody	NULL
(	NULL
Dako	NULL
;	NULL
no	NULL
.	NULL

F479	NULL
,	NULL
FITC-conjugated	NULL
)	NULL
.	NULL

Purified	NULL
human	NULL
IL-2	NULL
was	NULL
from	NULL
Schiapparelli	NULL
Biosystems	NULL
(	NULL
Woerden	NULL
,	NULL
The	NULL
Netherlands	NULL
)	NULL
.	NULL

SEA	NULL
was	NULL
from	NULL
Toxin	NULL
Technology	NULL
(	NULL
Madison	NULL
,	NULL
WI	NULL
;	NULL
no	NULL
.	NULL

BP202	NULL
)	NULL
,	NULL
and	NULL
SEB	NULL
was	NULL
from	NULL
Sigma	NULL
(	NULL
no	NULL
.	NULL

S	NULL
4881	NULL
)	NULL
.	NULL

The	NULL
enhanced	NULL
chemilumi-nescense	NULL
kit	NULL
was	NULL
from	NULL
Amersham	NULL
.	NULL

Cells	NULL
.	NULL

Allospecific	NULL
CD4*	NULL
human	NULL
T-cell	NULL
lines	NULL
have	NULL
been	NULL
described	NULL
(	NULL
35	NULL
,	NULL
36	NULL
)	NULL
.	NULL

Abbreviations	NULL
:	NULL
IL	NULL
,	NULL
interleukin	NULL
;	NULL
IL-2R	NULL
,	NULL
IL-2	NULL
receptor	NULL
;	NULL
Jak	NULL
,	NULL
Janus	NULL
protein-tyrosine	NULL
kinase	NULL
;	NULL
SE	NULL
,	NULL
Staphylococcus	NULL
aureus	NULL
entorotoxins	NULL
;	NULL
Stat	NULL
,	NULL
signal	NULL
transducers	NULL
and	NULL
activators	NULL
of	NULL
transcription	NULL
;	NULL
TCR	NULL
,	NULL
T-cell	NULL
receptor	NULL
;	NULL
Vs	NULL
,	NULL
variable	NULL
region	NULL
B	NULL
chain	NULL
;	NULL
APC	NULL
,	NULL
antigen-presenting	NULL
cells	NULL
;	NULL
MHC	NULL
,	NULL
major	NULL
histocompatibility	NULL
complex	NULL
;	NULL
EBV-LCL	NULL
,	NULL
Epstein-Barr	NULL
virus-transformed	NULL
B-lymphoblastoid	NULL
cell	NULL
line	NULL
;	NULL
FITC	NULL
,	NULL
fluorescein	NULL
isothiocya-nate	NULL
;	NULL
PE	NULL
,	NULL
phycoerythrin	NULL
;	NULL
FACS	NULL
,	NULL
fluorescence-activated	NULL
cell	NULL
sorting	NULL
;	NULL
mAb	NULL
,	NULL
monoclonal	NULL
antibody	NULL
.	NULL

*To	NULL
whom	NULL
reprint	NULL
requests	NULL
should	NULL
be	NULL
addressed	NULL
.	NULL

10996	NULL
_	NULL
Immunology	NULL
:	NULL
Nielsen	NULL
et	NULL
al	NULL
.	NULL

Proliferative	NULL
Assays	NULL
.	NULL

Assays	NULL
were	NULL
performed	NULL
in	NULL
RPMI	NULL
1640	NULL
culture	NULL
medium	NULL
(	NULL
GIBCO	NULL
)	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
(	NULL
vol/vol	NULL
)	NULL
pooled	NULL
human	NULL
serum	NULL
,	NULL
2	NULL
mM	NULL
L-glutamine	NULL
,	NULL
and	NULL
100	NULL
pg	NULL
of	NULL
penicillin	NULL
and	NULL
100	NULL
ug	NULL
of	NULL
streptomycin	NULL
(	NULL
Novo-Nordisk	NULL
,	NULL
Copenha-gen	NULL
)	NULL
per	NULL
ml	NULL
in	NULL
96-well	NULL
round-bottom	NULL
tissue	NULL
culture	NULL
plates	NULL
(	NULL
Nunc	NULL
)	NULL
with	NULL
a	NULL
final	NULL
volume	NULL
of	NULL
200	NULL
Ll	NULL
(	NULL
35	NULL
,	NULL
36	NULL
)	NULL
.	NULL

Twelve	NULL
hours	NULL
prior	NULL
to	NULL
harvest	NULL
,	NULL
[	NULL
*H	NULL
]	NULL
Jthymidine	NULL
[	NULL
1	NULL
wCi	NULL
(	NULL
37	NULL
kBq	NULL
)	NULL
per	NULL
well	NULL
)	NULL
was	NULL
added	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
harvested	NULL
onto	NULL
glass	NULL
fiber	NULL
filters	NULL
,	NULL
[	NULL
*H	NULL
}	NULL
thymidine	NULL
incorporation	NULL
was	NULL
measured	NULL
in	NULL
a	NULL
scintillation	NULL
counter	NULL
,	NULL
and	NULL
the	NULL
results	NULL
were	NULL
expressed	NULL
as	NULL
median	NULL
cpm	NULL
from	NULL
triplicate	NULL
cultures	NULL
(	NULL
35	NULL
,	NULL
36	NULL
)	NULL
.	NULL

Preincubation	NULL
and	NULL
Stimulation	NULL
of	NULL
Cells	NULL
.	NULL

Preincubation	NULL
with	NULL
SE	NULL
.	NULL

Cells	NULL
were	NULL
incubated	NULL
in	NULL
medium	NULL
containing	NULL
IL-2	NULL
(	NULL
50	NULL
units/ml	NULL
)	NULL
and	NULL
a	NULL
mixture	NULL
of	NULL
SEA	NULL
(	NULL
1	NULL
ug/ml	NULL
)	NULL
and	NULL
SEB	NULL
(	NULL
5	NULL
ug/ml	NULL
)	NULL
for	NULL
the	NULL
indicated	NULL
periods	NULL
of	NULL
time	NULL
.	NULL

Stimulation	NULL
with	NULL
IL-2	NULL
.	NULL

Prior	NULL
to	NULL
IL-2	NULL
treatment	NULL
,	NULL
cells	NULL
were	NULL
incubated	NULL
in	NULL
IL-2-free	NULL
medium	NULL
for	NULL
2	NULL
hr	NULL
.	NULL

The	NULL
subsequent	NULL
stimulation	NULL
with	NULL
IL-2	NULL
at	NULL
500	NULL
units/ml	NULL
was	NULL
carried	NULL
out	NULL
in	NULL
Eppendorf	NULL
tubes	NULL
at	NULL
15	NULL
X	NULL
10°	NULL
cells	NULL
per	NULL
ml	NULL
for	NULL
the	NULL
indicated	NULL
periods	NULL
of	NULL
time	NULL
.	NULL

~	NULL
Protein	NULL
Extraction	NULL
and	NULL
Western	NULL
Blotting	NULL
.	NULL

After	NULL
treatment	NULL
with	NULL
IL-2	NULL
and/or	NULL
SE	NULL
,	NULL
the	NULL
T	NULL
cells	NULL
(	NULL
3	NULL
x	NULL
10°	NULL
cells	NULL
per	NULL
experiment	NULL
for	NULL
analysis	NULL
of	NULL
total	NULL
phosphorylation	NULL
;	NULL
20	NULL
x	NULL
10°	NULL
cells	NULL
per	NULL
experiment	NULL
for	NULL
immunoprecipitations	NULL
)	NULL
were	NULL
rapidly	NULL
pelleted	NULL
,	NULL
and	NULL
the	NULL
reaction	NULL
was	NULL
stopped	NULL
by	NULL
lysing	NULL
the	NULL
cells	NULL
in	NULL
ice-cold	NULL
lysis	NULL
buffer	NULL
[	NULL
1	NULL
%	NULL
Nonidet	NULL
P-40/20	NULL
mM	NULL
Tris	NULL
,	NULL
pH	NULL
8.0/137	NULL
mM	NULL
NaCl/5	NULL
mM	NULL
MgCI1	NULL
;	NULL
/10	NULL
%	NULL
(	NULL
vol/vol	NULL
)	NULL
glycerol	NULL
containing	NULL
the	NULL
following	NULL
inhibitors	NULL
:	NULL
5	NULL
mM	NULL
EDTA	NULL
,	NULL
1	NULL
mM	NULL
NasVO4	NULL
,	NULL
10	NULL
ug	NULL
of	NULL
aprotinin	NULL
per	NULL
ml	NULL
,	NULL
4	NULL
uM	NULL
iodoacetamide	NULL
,	NULL
and	NULL
1	NULL
mM	NULL
phenylmethylsulfonyl	NULL
fluoride	NULL
]	NULL
.	NULL

Immunoblotting	NULL
and	NULL
immunoprecipitation	NULL
were	NULL
conducted	NULL
as	NULL
described	NULL
(	NULL
30	NULL
)	NULL
.	NULL

Blots	NULL
were	NULL
evaluated	NULL
by	NULL
enhanced	NULL
chemiluminescence	NULL
,	NULL
stripped	NULL
,	NULL
and	NULL
reprobed	NULL
according	NULL
to	NULL
the	NULL
manufacturers	NULL
'	NULL
directions	NULL
(	NULL
Amersham	NULL
)	NULL
.	NULL

FACS	NULL
Analysis	NULL
(	NULL
Analysis	NULL
of	NULL
Apoptosis	NULL
and	NULL
Cell	NULL
Surface	NULL
Antigen	NULL
Expression	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
analyzed	NULL
by	NULL
indirect	NULL
immu-nofluorescence	NULL
(	NULL
FACScan	NULL
,	NULL
Becton	NULL
Dickinson	NULL
)	NULL
as	NULL
described	NULL
(	NULL
37	NULL
)	NULL
.	NULL

The	NULL
percentage	NULL
of	NULL
positive	NULL
cells	NULL
was	NULL
corrected	NULL
for	NULL
background	NULL
by	NULL
subtracting	NULL
the	NULL
percentage	NULL
of	NULL
cells	NULL
that	NULL
stained	NULL
nonspecifically	NULL
with	NULL
a	NULL
nonbinding	NULL
antibody	NULL
of	NULL
similar	NULL
IgG	NULL
isotype	NULL
.	NULL

The	NULL
fraction	NULL
of	NULL
apoptotic	NULL
cells	NULL
was	NULL
determined	NULL
after	NULL
staining	NULL
DNA	NULL
with	NULL
propidium	NULL
iodide	NULL
(	NULL
Calbiochem	NULL
)	NULL
by	NULL
the	NULL
method	NULL
described	NULL
by	NULL
Vindeloev	NULL
et	NULL
al	NULL
.	NULL

(	NULL
38	NULL
)	NULL
,	NULL
and	NULL
analysis	NULL
was	NULL
performed	NULL
by	NULL
the	NULL
use	NULL
of	NULL
a	NULL
FACScan	NULL
research	NULL
software	NULL
program	NULL
(	NULL
LYSIS	NULL
I1	NULL
)	NULL
.	NULL

Usually	NULL
104	NULL
events	NULL
were	NULL
analyzed	NULL
.	NULL

A	NULL
logarithmic	NULL
scale	NULL
was	NULL
used	NULL
for	NULL
depicting	NULL
fluorescence	NULL
in	NULL
DNA	NULL
histo-grams	NULL
.	NULL

Small	NULL
molecular	NULL
debris	NULL
and	NULL
aggregates	NULL
were	NULL
excluded	NULL
by	NULL
gating	NULL
.	NULL

The	NULL
percentage	NULL
of	NULL
apoptotic	NULL
cells	NULL
with	NULL
hypodiploid	NULL
nuclei	NULL
was	NULL
calculated	NULL
from	NULL
histograms	NULL
as	NULL
:	NULL
%	NULL
apoptosis	NULL
=	NULL
[	NULL
no	NULL
.	NULL

of	NULL
hypodiploid	NULL
nuclei/total	NULL
no	NULL
.	NULL

of	NULL
nuclei	NULL
]	NULL
X	NULL
100	NULL
,	NULL
where	NULL
gates	NULL
were	NULL
set	NULL
both	NULL
for	NULL
hypodiploid	NULL
nuclei	NULL
and	NULL
for	NULL
hypodiploid	NULL
nuclei	NULL
+	NULL
diploid	NULL
to	NULL
tetraploid	NULL
nuclei	NULL
of	NULL
viable	NULL
cells	NULL
(	NULL
=	NULL
total	NULL
no	NULL
.	NULL

of	NULL
nuclei	NULL
)	NULL
.	NULL

RESULTS	NULL
SE	NULL
Preincubation	NULL
Inhibits	NULL
IL-2-Driven	NULL
Proliferation	NULL
.	NULL

Upon	NULL
activation	NULL
by	NULL
APC	NULL
,	NULL
human	NULL
T	NULL
cells	NULL
synthesize	NULL
and	NULL
express	NULL
MHC	NULL
class	NULL
II	NULL
molecules	NULL
.	NULL

Activated	NULL
T	NULL
cells	NULL
respond	NULL
to	NULL
IL-2	NULL
by	NULL
proliferation	NULL
.	NULL

SE	NULL
binding	NULL
to	NULL
MHC	NULL
class	NULL
II*	NULL
allospecific	NULL
T-cell	NULL
lines	NULL
induces	NULL
tyrosine	NULL
kinase	NULL
activity	NULL
and	NULL
phosphatidylinositol	NULL
turnover	NULL
and	NULL
may	NULL
lead	NULL
to	NULL
an	NULL
inhibition	NULL
of	NULL
cytokine-driven	NULL
proliferation	NULL
(	NULL
refs	NULL
.	NULL

8	NULL
,	NULL
9	NULL
,	NULL
39	NULL
,	NULL
and	NULL
40	NULL
and	NULL
reviewed	NULL
in	NULL
ref	NULL
.	NULL

41	NULL
)	NULL
.	NULL

Exposure	NULL
to	NULL
a	NULL
mixture	NULL
of	NULL
SEA	NULL
and	NULL
SEB	NULL
induced	NULL
a	NULL
profound	NULL
inhibition	NULL
of	NULL
IL-2-driven	NULL
growth	NULL
of	NULL
human	NULL
allospecific	NULL
CD4	NULL
#	NULL
*	NULL
T	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
after	NULL
4	NULL
hr	NULL
of	NULL
SE	NULL
treatment	NULL
,	NULL
the	NULL
proliferative	NULL
response	NULL
was	NULL
inhibited	NULL
by	NULL
>	NULL
60	NULL
%	NULL
,	NULL
whereas	NULL
16	NULL
hr	NULL
of	NULL
SE	NULL
treatment	NULL
induced	NULL
an	NULL
almost	NULL
complete	NULL
block	NULL
of	NULL
cytokine-driven	NULL
proliferation	NULL
(	NULL
Fig	NULL
.	NULL

14	NULL
)	NULL
.	NULL

SE-induced	NULL
growth	NULL
inhibition	NULL
was	NULL
largely	NULL
reversed	NULL
by	NULL
irradiated	NULL
APC	NULL
such	NULL
as	NULL
Epstein-Barr	NULL
virus-transformed	NULL
B-lymphoblastoid	NULL
cell	NULL
line	NULL
(	NULL
EBV-LCL	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
92	NULL
(	NULL
1995	NULL
)	NULL
A	NULL
IL-2	NULL
B	NULL
APC	NULL
C	NULL
60	NULL
o	NULL
60	NULL
o	NULL
o	NULL
:	NULL
40	NULL
ye	NULL
40	NULL
3	NULL
3	NULL
i	NULL
o	NULL
20	NULL
o	NULL
20	NULL
o	NULL
--	NULL
-o	NULL
--	NULL
-0	NULL
--	NULL
6	NULL
O	NULL
--	NULL
o	NULL
--	NULL
-O0	NULL
--	NULL
o	NULL
or	NULL
--	NULL
-	NULL
T-4	NULL
8	NULL
16	NULL
4	NULL
8	NULL
16	NULL
SE	NULL
treatment	NULL
SE	NULL
treatment	NULL
(	NULL
hours	NULL
)	NULL
(	NULL
hours	NULL
)	NULL
al	NULL
C	NULL
£	NULL
90	NULL
5	NULL
=	NULL
60	NULL
a	NULL
r=	NULL
£	NULL
30	NULL
4	NULL
8	NULL
16	NULL
SE	NULL
treatment	NULL
(	NULL
hours	NULL
)	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Effect	NULL
of	NULL
SE	NULL
preincubation	NULL
on	NULL
IL-2-induced	NULL
T-cell	NULL
proliferation	NULL
.	NULL

(	NULL
4	NULL
and	NULL
B	NULL
)	NULL
CD4*	NULL
T	NULL
cells	NULL
(	NULL
5	NULL
X	NULL
104	NULL
cells	NULL
per	NULL
well	NULL
)	NULL
were	NULL
preincubated	NULL
in	NULL
medium	NULL
or	NULL
a	NULL
mixture	NULL
of	NULL
SEA	NULL
and	NULL
SEB	NULL
(	NULL
1	NULL
ug/ml	NULL
each	NULL
)	NULL
for	NULL
the	NULL
indicated	NULL
periods	NULL
of	NULL
time	NULL
and	NULL
were	NULL
washed	NULL
extensively	NULL
prior	NULL
to	NULL
culture	NULL
with	NULL
(	NULL
@	NULL
)	NULL
or	NULL
without	NULL
(	NULL
0	NULL
)	NULL
exogeneous	NULL
IL-2	NULL
at	NULL
100	NULL
units/ml	NULL
(	NULL
4	NULL
)	NULL
or	NULL
were	NULL
cocultured	NULL
with	NULL
irradiated	NULL
(	NULL
8000	NULL
rad	NULL
)	NULL
,	NULL
MHC-compatible	NULL
,	NULL
EBV-LCL	NULL
cells	NULL
(	NULL
25	NULL
x	NULL
104	NULL
per	NULL
well	NULL
)	NULL
with	NULL
(	NULL
@	NULL
)	NULL
or	NULL
without	NULL
(	NULL
0	NULL
)	NULL
SEA/SEB	NULL
at	NULL
1	NULL
ug/ml	NULL
each	NULL
.	NULL

uptake	NULL
was	NULL
measured	NULL
after	NULL
72	NULL
hr	NULL
of	NULL
culture	NULL
at	NULL
37°C	NULL
in	NULL
an	NULL
atmosphere	NULL
of	NULL
5	NULL
%	NULL
CO	NULL
;	NULL
/95	NULL
%	NULL
air	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Six	NULL
additional	NULL
T-cell	NULL
lines	NULL
were	NULL
preincubated	NULL
with	NULL
or	NULL
without	NULL
SE	NULL
prior	NULL
to	NULL
72	NULL
hr	NULL
of	NULL
culture	NULL
with	NULL
or	NULL
without	NULL
SE	NULL
and	NULL
IL-2	NULL
as	NULL
in	NULL
4	NULL
.	NULL

The	NULL
percentage	NULL
inhibition	NULL
by	NULL
SE	NULL
of	NULL
IL-2-driven	NULL
growth	NULL
was	NULL
calculated	NULL
according	NULL
to	NULL
the	NULL
formula	NULL
:	NULL
%	NULL
inhibition	NULL
=	NULL
[	NULL
(	NULL
IL-2	NULL
-	NULL
med	NULL
.	NULL
)	NULL

-	NULL
(	NULL
test	NULL
-	NULL
test	NULL
.	NULL

med	NULL
.	NULL
)	NULL

]	NULL
/	NULL
[	NULL
IL-2	NULL
-	NULL
med	NULL
.	NULL
]	NULL

X	NULL
100	NULL
,	NULL
in	NULL
which	NULL
``	NULL
IL-2	NULL
``	NULL
and	NULL
``	NULL
med	NULL
.	NULL
``	NULL

indicate	NULL
cpm	NULL
obtained	NULL
in	NULL
cultures	NULL
with	NULL
and	NULL
without	NULL
IL-2	NULL
,	NULL
respectively	NULL
.	NULL

``	NULL
Test	NULL
``	NULL
and	NULL
``	NULL
test	NULL
.	NULL

med	NULL
``	NULL
indicate	NULL
cpm	NULL
obtained	NULL
in	NULL
cultures	NULL
pretreated	NULL
with	NULL
SE	NULL
prior	NULL
to	NULL
culture	NULL
with	NULL
and	NULL
without	NULL
IL-2	NULL
,	NULL
respectively	NULL
.	NULL

The	NULL
mean	NULL
inhibition	NULL
(	NULL
@	NULL
)	NULL
of	NULL
six	NULL
experiments	NULL
is	NULL
shown	NULL
.	NULL

Bars	NULL
indicate	NULL
+2	NULL
SD	NULL
.	NULL

(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

In	NULL
an	NULL
independent	NULL
series	NULL
of	NULL
experiments	NULL
,	NULL
SE	NULL
treatment	NULL
induced	NULL
significant	NULL
inhibition	NULL
(	NULL
between	NULL
61	NULL
%	NULL
and	NULL
84	NULL
%	NULL
)	NULL
of	NULL
IL-2-driven	NULL
proliferation	NULL
in	NULL
all	NULL
of	NULL
six	NULL
additional	NULL
T-cell	NULL
lines	NULL
tested	NULL
(	NULL
Fig	NULL
.	NULL

1C	NULL
,	NULL
P	NULL
<	NULL
0.05	NULL
Willcoxon	NULL
's	NULL
rank	NULL
sum	NULL
test	NULL
)	NULL
.	NULL

These	NULL
findings	NULL
are	NULL
in	NULL
accord	NULL
with	NULL
a	NULL
recent	NULL
report	NULL
by	NULL
Damle	NULL
et	NULL
al	NULL
.	NULL

(	NULL
12	NULL
)	NULL
that	NULL
SE	NULL
treatment	NULL
of	NULL
human	NULL
CD4*	NULL
T-cell	NULL
lines	NULL
induced	NULL
a	NULL
state	NULL
of	NULL
antigen	NULL
and	NULL
cytokine	NULL
nonresponsiveness	NULL
that	NULL
could	NULL
be	NULL
abrogated	NULL
by	NULL
coculture	NULL
with	NULL
EBV-LCL	NULL
.	NULL

SE	NULL
Inhibition	NULL
of	NULL
Proliferation	NULL
Is	NULL
Accompanied	NULL
by	NULL
Alterations	NULL
in	NULL
IL-2R	NULL
Composition	NULL
.	NULL

In	NULL
search	NULL
for	NULL
a	NULL
possible	NULL
explanation	NULL
for	NULL
the	NULL
inhibition	NULL
of	NULL
IL-2-induced	NULL
proliferation	NULL
,	NULL
we	NULL
analyzed	NULL
the	NULL
effect	NULL
of	NULL
SE	NULL
on	NULL
the	NULL
expression	NULL
of	NULL
individual	NULL
IL-2R	NULL
chains	NULL
.	NULL

FACS	NULL
analysis	NULL
showed	NULL
that	NULL
the	NULL
expression	NULL
of	NULL
IL-2Ra	NULL
,	NULL
-B	NULL
,	NULL
and	NULL
-y	NULL
chains	NULL
was	NULL
affected	NULL
differently	NULL
by	NULL
SE	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
expression	NULL
of	NULL
IL-2R	NULL
$	NULL
chains	NULL
was	NULL
down-regulated	NULL
as	NULL
early	NULL
as	NULL
1	NULL
hr	NULL
after	NULL
SE	NULL
addition	NULL
and	NULL
reduced	NULL
to	NULL
~50	NULL
%	NULL
after	NULL
16	NULL
hr	NULL
of	NULL
exposure	NULL
to	NULL
SE	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
y-chain	NULL
expression	NULL
was	NULL
slightly	NULL
up-regulated	NULL
after	NULL
4	NULL
and	NULL
16	NULL
hr	NULL
of	NULL
SE	NULL
treatment	NULL
.	NULL

The	NULL
expression	NULL
of	NULL
IL-2R	NULL
a	NULL
chains	NULL
remained	NULL
relatively	NULL
constant	NULL
after	NULL
4	NULL
hr	NULL
of	NULL
SE	NULL
treatment	NULL
,	NULL
whereas	NULL
an	NULL
increased	NULL
IL-2Ra	NULL
expression	NULL
could	NULL
be	NULL
observed	NULL
after	NULL
16	NULL
hr	NULL
of	NULL
exposure	NULL
to	NULL
SE	NULL
,	NULL
indicating	NULL
that	NULL
SE	NULL
induced	NULL
selective	NULL
and	NULL
dynamic	NULL
changes	NULL
in	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
individual	NULL
IL-2R	NULL
chains	NULL
.	NULL

This	NULL
conclusion	NULL
was	NULL
supported	NULL
by	NULL
our	NULL
observation	NULL
that	NULL
other	NULL
surface	NULL
molecules	NULL
were	NULL
also	NULL
individually	NULL
affected	NULL
by	NULL
SE	NULL
.	NULL

Thus	NULL
,	NULL
SE	NULL
induced	NULL
a	NULL
significant	NULL
up-regulation	NULL
of	NULL
intercellular	NULL
cell-adhesion	NULL
molecule	NULL
1	NULL
and	NULL
downregulation	NULL
of	NULL
CDS	NULL
expression	NULL
,	NULL
while	NULL
the	NULL
expression	NULL
of	NULL
CD38	NULL
remained	NULL
largely	NULL
unaffected	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Immunology	NULL
:	NULL
Nielsen	NULL
et	NULL
al	NULL
.	NULL

105	NULL
--	NULL
Oh	NULL
...	NULL
..	NULL
1h	NULL
--	NULL
--	NULL
-	NULL
4h	NULL
--	NULL
16h	NULL
Control	NULL
0	NULL
100	NULL
101	NULL
102	NULL
10	NULL
104	NULL
103	NULL
=o	NULL
0°	NULL
10	NULL
!	NULL

102	NULL
103	NULL
104	NULL
108	NULL
10	NULL
___	NULL
10	NULL
102	NULL
10	NULL
10¢	NULL
IL-2Ry	NULL
***p	NULL
To	NULL
ICAM-1	NULL
w	NULL
-__	NULL
101	NULL
10°	NULL
105	NULL
Tos	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

Effect	NULL
of	NULL
SE	NULL
incubation	NULL
on	NULL
IL-2R	NULL
expression	NULL
.	NULL

Cells	NULL
were	NULL
preincubated	NULL
in	NULL
medium	NULL
or	NULL
medium	NULL
including	NULL
SE	NULL
for	NULL
the	NULL
indicated	NULL
periods	NULL
of	NULL
time	NULL
prior	NULL
to	NULL
flow	NULL
cytometric	NULL
examination	NULL
with	NULL
antibodies	NULL
against	NULL
IL-2Ra	NULL
(	NULL
CD25	NULL
,	NULL
IOTi4a	NULL
,	NULL
FITC-conjugated	NULL
)	NULL
,	NULL
IL-2R	NULL
$	NULL
B	NULL
(	NULL
p75	NULL
,	NULL
PE-conjugated	NULL
)	NULL
,	NULL
IL-2Ry	NULL
(	NULL
TUGh4	NULL
)	NULL
,	NULL
ICAM-1	NULL
(	NULL
CD54	NULL
,	NULL
84H10	NULL
,	NULL
PE-conjugated	NULL
)	NULL
,	NULL
or	NULL
secondary	NULL
antibody	NULL
(	NULL
goat	NULL
anti-mouse	NULL
,	NULL
FITC-conjugated	NULL
)	NULL
.	NULL

These	NULL
data	NULL
were	NULL
representative	NULL
from	NULL
four	NULL
independent	NULL
experiments	NULL
.	NULL

SE	NULL
Induce	NULL
Changes	NULL
in	NULL
Early	NULL
IL-2R	NULL
Signaling	NULL
.	NULL

Because	NULL
SE	NULL
induced	NULL
changes	NULL
in	NULL
the	NULL
relative	NULL
amount	NULL
of	NULL
the	NULL
individual	NULL
IL-2R	NULL
components	NULL
,	NULL
we	NULL
examined	NULL
whether	NULL
an	NULL
altered	NULL
IL-2R	NULL
compo-	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
92	NULL
(	NULL
1995	NULL
)	NULL
-	NULL
10997	NULL
sition	NULL
resulted	NULL
in	NULL
changes	NULL
in	NULL
receptor	NULL
signaling	NULL
.	NULL

Recently	NULL
,	NULL
it	NULL
was	NULL
reported	NULL
that	NULL
the	NULL
B	NULL
and	NULL
the	NULL
a	NULL
chains	NULL
,	NULL
as	NULL
well	NULL
as	NULL
the	NULL
B	NULL
and	NULL
y	NULL
chains	NULL
,	NULL
are	NULL
able	NULL
to	NULL
bind	NULL
to	NULL
each	NULL
other	NULL
,	NULL
whereas	NULL
the	NULL
y	NULL
and	NULL
the	NULL
a	NULL
chains	NULL
can	NULL
not	NULL
associate	NULL
without	NULL
the	NULL
B	NULL
chain	NULL
being	NULL
present	NULL
(	NULL
42	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
regulation	NULL
of	NULL
B-chain	NULL
expression	NULL
may	NULL
be	NULL
an	NULL
important	NULL
mechanism	NULL
for	NULL
limiting	NULL
the	NULL
response	NULL
to	NULL
IL-2	NULL
.	NULL

To	NULL
study	NULL
the	NULL
early	NULL
intracellular	NULL
signaling	NULL
events	NULL
,	NULL
we	NULL
incubated	NULL
cells	NULL
with	NULL
SE	NULL
for	NULL
different	NULL
periods	NULL
of	NULL
time	NULL
and	NULL
subsequently	NULL
stimulated	NULL
them	NULL
with	NULL
medium	NULL
or	NULL
IL-2	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
then	NULL
lysed	NULL
,	NULL
and	NULL
IL-2-induced	NULL
tyrosine	NULL
phosphorylations	NULL
were	NULL
analyzed	NULL
by	NULL
SDS/PAGE	NULL
and	NULL
immunoblotting	NULL
with	NULL
anti-phosphotyrosine	NULL
mAb	NULL
.	NULL

IL-2	NULL
induced	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
several	NULL
proteins	NULL
,	NULL
the	NULL
predominant	NULL
ones	NULL
being	NULL
substrates	NULL
with	NULL
a	NULL
molecular	NULL
weight	NULL
of	NULL
~90-100	NULL
kDa	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

The	NULL
phosphorylation	NULL
reached	NULL
a	NULL
maximum	NULL
after	NULL
10	NULL
min	NULL
of	NULL
IL-2	NULL
stimulation	NULL
and	NULL
declined	NULL
to	NULL
the	NULL
background	NULL
level	NULL
after	NULL
1	NULL
hr	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
lanes	NULL
1-3	NULL
)	NULL
.	NULL

Whereas	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
the	NULL
90-	NULL
to	NULL
100-kDa	NULL
proteins	NULL
was	NULL
only	NULL
weakly	NULL
inhibited	NULL
after	NULL
1	NULL
hr	NULL
of	NULL
SE	NULL
preincubation	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
lanes	NULL
4-6	NULL
)	NULL
,	NULL
4	NULL
hr	NULL
of	NULL
SE	NULL
treatment	NULL
strongly	NULL
inhibited	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
these	NULL
proteins	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
lanes	NULL
7-9	NULL
)	NULL
.	NULL

The	NULL
profound	NULL
inhibition	NULL
by	NULL
SE	NULL
of	NULL
IL-2-induced	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
the	NULL
90-	NULL
to	NULL
100-kDa	NULL
proteins	NULL
was	NULL
not	NULL
due	NULL
to	NULL
a	NULL
delay	NULL
in	NULL
kinetics	NULL
,	NULL
since	NULL
neither	NULL
10	NULL
min	NULL
nor	NULL
60	NULL
min	NULL
of	NULL
IL-2	NULL
stimulation	NULL
induced	NULL
higher	NULL
levels	NULL
of	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
the	NULL
proteins	NULL
in	NULL
question	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
lanes	NULL
7-9	NULL
)	NULL
.	NULL

Surprisingly	NULL
,	NULL
T	NULL
cells	NULL
had	NULL
partly	NULL
regained	NULL
their	NULL
tyrosine	NULL
phosphorylation	NULL
capacity	NULL
after	NULL
16	NULL
hr	NULL
of	NULL
SE	NULL
incubation	NULL
(	NULL
lanes	NULL
10-12	NULL
)	NULL
.	NULL

Recently	NULL
,	NULL
it	NULL
was	NULL
shown	NULL
that	NULL
the	NULL
IL-2	NULL
receptor	NULL
is	NULL
coupled	NULL
to	NULL
the	NULL
newly	NULL
identified	NULL
JAK/Stat	NULL
signaling	NULL
pathway-i.e	NULL
.	NULL

,	NULL
IL-2	NULL
stimulation	NULL
induces	NULL
tyrosine	NULL
phosphorylation	NULL
and	NULL
nuclear	NULL
translocation	NULL
of	NULL
Stat3	NULL
and	NULL
Stat5	NULL
proteins	NULL
in	NULL
human	NULL
T	NULL
cells	NULL
(	NULL
30	NULL
,	NULL
32	NULL
,	NULL
33	NULL
)	NULL
.	NULL

These	NULL
Stat	NULL
proteins	NULL
have	NULL
molecular	NULL
weights	NULL
similar	NULL
to	NULL
those	NULL
of	NULL
the	NULL
proteins	NULL
affected	NULL
by	NULL
SE	NULL
treatment	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

Accordingly	NULL
,	NULL
we	NULL
examined	NULL
whether	NULL
the	NULL
JAK/Stat	NULL
signaling	NULL
pathway	NULL
was	NULL
defective	NULL
in	NULL
SE-treated	NULL
cells	NULL
.	NULL

To	NULL
investigate	NULL
this	NULL
,	NULL
IL-2-induced	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
Jak3	NULL
was	NULL
measured	NULL
in	NULL
cells	NULL
treated	NULL
with	NULL
SE	NULL
or	NULL
medium	NULL
for	NULL
4	NULL
hr	NULL
(	NULL
Fig	NULL
.	NULL

44	NULL
Upper	NULL
)	NULL
.	NULL

Whereas	NULL
IL-2	NULL
induced	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
Jak3	NULL
in	NULL
medium-treated	NULL
cells	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
,	NULL
IL-2	NULL
induced	NULL
weak	NULL
,	NULL
barely	NULL
detectable	NULL
levels	NULL
of	NULL
Jak3	NULL
tyrosine	NULL
phosphorylation	NULL
in	NULL
SE-treated	NULL
cells	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
.	NULL

The	NULL
defective	NULL
Jak3	NULL
activation	NULL
was	NULL
not	NULL
caused	NULL
by	NULL
degradation	NULL
of	NULL
the	NULL
kinase	NULL
,	NULL
since	NULL
the	NULL
amount	NULL
of	NULL
Jak3	NULL
precipitated	NULL
was	NULL
not	NULL
decreased	NULL
after	NULL
SE	NULL
treatment	NULL
(	NULL
Fig	NULL
.	NULL

44	NULL
Lower	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
in	NULL
addition	NULL
to	NULL
(	NULL
or	NULL
as	NULL
a	NULL
consequence	NULL
of	NULL
)	NULL
the	NULL
effect	NULL
on	NULL
IL-2RB-chain	NULL
expression	NULL
,	NULL
SE	NULL
seemed	NULL
to	NULL
inhibit	NULL
Jak3	NULL
activation	NULL
.	NULL

The	NULL
JAK	NULL
kinases	NULL
are	NULL
believed	NULL
to	NULL
be	NULL
the	NULL
immediate	NULL
activators	NULL
of	NULL
Stat	NULL
proteins	NULL
,	NULL
and	NULL
we	NULL
therefore	NULL
examined	NULL
whether	NULL
the	NULL
activation	NULL
of	NULL
Stat	NULL
proteins	NULL
was	NULL
also	NULL
inhibited	NULL
in	NULL
the	NULL
SE-treated	NULL
cells	NULL
.	NULL

Indeed	NULL
,	NULL
IL-2-induced	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
both	NULL
Stat3	NULL
and	NULL
Stat5	NULL
was	NULL
decreased	NULL
after	NULL
4	NULL
hr	NULL
of	NULL
exposure	NULL
to	NULL
SE	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
,	NULL
compare	NULL
lanes	NULL
1-4	NULL
and	NULL
lanes	NULL
5-8	NULL
)	NULL
.	NULL

Intriguingly	NULL
,	NULL
as	NULL
detected	NULL
in	NULL
the	NULL
phosphotyrosine	NULL
immunoblot	NULL
of	NULL
total	NULL
cellular	NULL
lysates	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
,	NULL
SE	NULL
(	NULL
hours	NULL
)	NULL
:	NULL
0	NULL
0	NULL
0	NULL
1	NULL
age	NULL
4	NULL
-	NULL
4	NULL
4	NULL
16	NULL
16	NULL
16	NULL
IL-2	NULL
(	NULL
min	NULL
)	NULL
:	NULL
O0	NULL
10	NULL
60	NULL
0	NULL
10	NULL
60	NULL
O0	NULL
10	NULL
60	NULL
0	NULL
10	NULL
60	NULL
200	NULL
..	NULL
me	NULL
-	NULL
@	NULL
w	NULL
69	NULL
-	NULL
kh	NULL
(	NULL
%	NULL
Lane	NULL
4.49	NULL
%	NULL
0°	NULL
``	NULL
Ta-	NULL
.	NULL

9	NULL
.	NULL

10	NULL
A112	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

Altered	NULL
IL-2-induced	NULL
tyrosine	NULL
phosphorylation	NULL
following	NULL
SE	NULL
preincubation	NULL
.	NULL

Cells	NULL
were	NULL
incubated	NULL
without	NULL
(	NULL
lanes	NULL
1-3	NULL
)	NULL
or	NULL
with	NULL
SE	NULL
for	NULL
1	NULL
(	NULL
lanes	NULL
4-6	NULL
)	NULL
,	NULL
4	NULL
(	NULL
lanes	NULL
7-9	NULL
)	NULL
,	NULL
or	NULL
16	NULL
(	NULL
lanes	NULL
10-12	NULL
)	NULL
hr	NULL
before	NULL
stimulation	NULL
for	NULL
10	NULL
(	NULL
lanes	NULL
2	NULL
,	NULL
5	NULL
,	NULL
8	NULL
,	NULL
and	NULL
11	NULL
)	NULL
or	NULL
60	NULL
(	NULL
lanes	NULL
3	NULL
,	NULL
6	NULL
,	NULL
9	NULL
,	NULL
and	NULL
12	NULL
)	NULL
min	NULL
with	NULL
IL-2	NULL
at	NULL
500	NULL
units/ml	NULL
.	NULL

Cells	NULL
were	NULL
lysed	NULL
,	NULL
and	NULL
IL-2-induced	NULL
tyrosine	NULL
phosphorylation	NULL
was	NULL
analyzed	NULL
by	NULL
Western	NULL
blotting	NULL
with	NULL
an	NULL
anti-phosphotyrosine	NULL
mAb	NULL
(	NULL
4G10	NULL
)	NULL
.	NULL

The	NULL
positions	NULL
of	NULL
prestained	NULL
molecular	NULL
standards	NULL
(	NULL
Amersham	NULL
)	NULL
are	NULL
indicated	NULL
on	NULL
the	NULL
left	NULL
in	NULL
kDa	NULL
.	NULL

These	NULL
data	NULL
were	NULL
representative	NULL
from	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

10998	NULL
_	NULL
Immunology	NULL
:	NULL
Nielsen	NULL
et	NULL
al	NULL
.	NULL

B	NULL
A	NULL
Blot	NULL
Ab	NULL
:	NULL
SE	NULL
(	NULL
hours	NULL
)	NULL
:	NULL
O0	NULL
_	NULL
O0	NULL
4	NULL
4	NULL
SE	NULL
(	NULL
hours	NULL
)	NULL
:	NULL
IL-2	NULL
:	NULL
-/	NULL
.	NULL

+	NULL
a	NULL
+	NULL
IL-2	NULL
:	NULL
Blot	NULL
:	NULL
P-tyr	NULL
*	NULL
<	NULL
Jak3	NULL
Blot	NULL
:	NULL
Jak3	NULL
-	NULL
M	NULL
aad	NULL
wae	NULL
whes	NULL
Lane	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
92	NULL
(	NULL
1995	NULL
)	NULL
stats	NULL
stat3	NULL
stats	NULL
stat3	NULL
stat5	NULL
0	NULL
0	NULL
0	NULL
o	NULL
44	NULL
.	NULL

4	NULL
.	NULL

14	NULL
``	NULL
ls	NULL
ie	NULL
i6	NULL
T6	NULL
a	NULL
mip	NULL
o	NULL
2	NULL
oop	NULL
pip	NULL
cs	NULL
g	NULL
en	NULL
p	NULL
``	NULL
.	NULL
``	NULL

-+	NULL
_	NULL
;	NULL
-	NULL
stats	NULL
s	NULL
t=	NULL
~-	NULL
stat3	NULL
3°	NULL
4	NULL
;	NULL
``	NULL
S	NULL
``	NULL
%	NULL
.~	NULL
:	NULL
F-	NULL
:	NULL
%	NULL
:	NULL
0:10	NULL
(	NULL
IL	NULL
.	NULL

,	NULL
12	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

-	NULL
SE	NULL
treatment	NULL
inhibits	NULL
IL-2-induced	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
Jak3-	NULL
,	NULL
Stat3-	NULL
,	NULL
and	NULL
Stat5-like	NULL
proteins	NULL
.	NULL

Cells	NULL
were	NULL
preincubated	NULL
with	NULL
or	NULL
without	NULL
SE	NULL
for	NULL
the	NULL
indicated	NULL
periods	NULL
of	NULL
time	NULL
.	NULL

Cells	NULL
were	NULL
then	NULL
stimulated	NULL
for	NULL
10	NULL
min	NULL
with	NULL
IL-2	NULL
at	NULL
500	NULL
units/ml	NULL
,	NULL
lysed	NULL
,	NULL
and	NULL
analyzed	NULL
by	NULL
immunoprecipitation	NULL
and	NULL
blotting	NULL
experiments	NULL
.	NULL

(	NULL
4	NULL
Upper	NULL
)	NULL
Lysates	NULL
were	NULL
immunoprecipitated	NULL
with	NULL
anti-Jak3	NULL
antibody	NULL
(	NULL
no	NULL
.	NULL

06-428	NULL
,	NULL
UBI	NULL
)	NULL
and	NULL
immunoblotted	NULL
with	NULL
anti-phosphotyrosine	NULL
mAb	NULL
(	NULL
4610	NULL
)	NULL
.	NULL

(	NULL
4	NULL
Lower	NULL
)	NULL
The	NULL
nitrocellulose	NULL
shown	NULL
in	NULL
Upper	NULL
was	NULL
stripped	NULL
and	NULL
reprobed	NULL
with	NULL
anti-Jak3	NULL
Ab	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Lysates	NULL
were	NULL
immunoprecipitated	NULL
with	NULL
anti-phosphotyrosine	NULL
mAb	NULL
and	NULL
blotted	NULL
with	NULL
Stat3	NULL
mAb	NULL
(	NULL
no	NULL
.	NULL

$	NULL
21320	NULL
,	NULL
Transduction	NULL
Laboratories	NULL
)	NULL
(	NULL
lanes	NULL
1	NULL
,	NULL
2	NULL
,	NULL
5	NULL
,	NULL
6	NULL
,	NULL
9	NULL
,	NULL
and	NULL
10	NULL
)	NULL
or	NULL
Stats	NULL
mAb	NULL
(	NULL
no	NULL
.	NULL

$	NULL
21520	NULL
,	NULL
Transduction	NULL
Laboratories	NULL
)	NULL
(	NULL
lanes	NULL
3	NULL
,	NULL
4	NULL
,	NULL
7	NULL
,	NULL
8	NULL
,	NULL
11	NULL
,	NULL
and	NULL
12	NULL
)	NULL
.	NULL

Essentially	NULL
identical	NULL
results	NULL
were	NULL
obtained	NULL
in	NULL
an	NULL
additional	NULL
experiment	NULL
.	NULL

the	NULL
ability	NULL
to	NULL
tyrosine-phosphorylate	NULL
the	NULL
Stat	NULL
proteins	NULL
was	NULL
partly	NULL
recovered	NULL
after	NULL
16	NULL
hr	NULL
of	NULL
SE	NULL
pretreatment	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
,	NULL
lanes	NULL
9-12	NULL
)	NULL
.	NULL

The	NULL
reconstitution	NULL
of	NULL
early	NULL
Jak3/Stat	NULL
signaling	NULL
did	NULL
not	NULL
correlate	NULL
with	NULL
a	NULL
regained	NULL
proliferative	NULL
response	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

SE-Induced	NULL
Anergy/Apoptosis	NULL
Can	NULL
not	NULL
Be	NULL
Reversed	NULL
by	NULL
IL-2	NULL
.	NULL

In	NULL
a	NULL
recent	NULL
report	NULL
,	NULL
the	NULL
IL-2Ry	NULL
chain	NULL
and	NULL
Jak3	NULL
have	NULL
been	NULL
proposed	NULL
to	NULL
be	NULL
involved	NULL
in	NULL
IL-2-mediated	NULL
conversion	NULL
of	NULL
(	NULL
res-cue	NULL
from	NULL
)	NULL
anergy	NULL
and	NULL
apoptosis	NULL
(	NULL
43	NULL
)	NULL
.	NULL

In	NULL
the	NULL
present	NULL
study	NULL
,	NULL
the	NULL
expression	NULL
of	NULL
IL-2Ry	NULL
was	NULL
increased	NULL
following	NULL
SE	NULL
treatment	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
and	NULL
,	NULL
although	NULL
IL-2-induced	NULL
Jak3	NULL
tyrosine	NULL
phosphorylation	NULL
was	NULL
inhibited	NULL
,	NULL
the	NULL
level	NULL
of	NULL
Jak3	NULL
was	NULL
not	NULL
decreased	NULL
.	NULL

Therefore	NULL
,	NULL
we	NULL
investigated	NULL
whether	NULL
SE-induced	NULL
apoptosis	NULL
could	NULL
be	NULL
reversed	NULL
by	NULL
IL-2	NULL
.	NULL

Accordingly	NULL
,	NULL
after	NULL
4	NULL
hr	NULL
of	NULL
exposure	NULL
to	NULL
SE	NULL
or	NULL
medium	NULL
,	NULL
T	NULL
cells	NULL
were	NULL
cultured	NULL
with	NULL
exogeneous	NULL
IL-2	NULL
for	NULL
another	NULL
24	NULL
or	NULL
48	NULL
hr	NULL
prior	NULL
to	NULL
flow	NULL
cytometric	NULL
analysis	NULL
of	NULL
apoptosis	NULL
.	NULL

SE	NULL
induced	NULL
only	NULL
little	NULL
apoptosis	NULL
after	NULL
4	NULL
hr	NULL
of	NULL
preincubation	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
,	NULL
whereas	NULL
a	NULL
significant	NULL
increase	NULL
in	NULL
the	NULL
fraction	NULL
of	NULL
apoptotic	NULL
cells	NULL
could	NULL
be	NULL
seen	NULL
after	NULL
24	NULL
and	NULL
48	NULL
hr	NULL
.	NULL

Thus	NULL
,	NULL
after	NULL
48	NULL
hr	NULL
of	NULL
culture	NULL
with	NULL
IL-2	NULL
,	NULL
the	NULL
fraction	NULL
of	NULL
apoptotic	NULL
cells	NULL
was	NULL
approximately	NULL
3	NULL
times	NULL
higher	NULL
in	NULL
SE-treated	NULL
cultures	NULL
than	NULL
in	NULL
parallel	NULL
cultures	NULL
without	NULL
SE	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

This	NULL
observation	NULL
is	NULL
in	NULL
accordance	NULL
with	NULL
other	NULL
data	NULL
showing	NULL
that	NULL
SE-induced	NULL
anergy/apoptosis	NULL
can	NULL
not	NULL
be	NULL
reversed	NULL
by	NULL
IL-2	NULL
(	NULL
12	NULL
,	NULL
44	NULL
)	NULL
.	NULL

Our	NULL
findings	NULL
that	NULL
SE-treated	NULL
cells	NULL
express	NULL
little	NULL
IL-2R	NULL
$	NULL
chain	NULL
and	NULL
are	NULL
defective	NULL
in	NULL
activating	NULL
Jak3	NULL
could	NULL
explain	NULL
why	NULL
SE-induced	NULL
anergy	NULL
and	NULL
apoptosis	NULL
could	NULL
not	NULL
be	NULL
reversed	NULL
by	NULL
exogeneous	NULL
It	NULL
is	NULL
well-known	NULL
that	NULL
withdrawal	NULL
of	NULL
IL-2	NULL
from	NULL
activated	NULL
T	NULL
cells	NULL
induces	NULL
a	NULL
massive	NULL
apoptotic	NULL
response	NULL
(	NULL
reviewed	NULL
in	NULL
ref	NULL
.	NULL

45	NULL
)	NULL
.	NULL

We	NULL
also	NULL
found	NULL
high	NULL
levels	NULL
of	NULL
apoptosis	NULL
in	NULL
IL-2-starved	NULL
cultures	NULL
(	NULL
58	NULL
%	NULL
apoptosis	NULL
,	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

SE	NULL
preincubation	NULL
prior	NULL
to	NULL
IL-2	NULL
starvation	NULL
induced	NULL
70-80	NULL
%	NULL
apoptosis	NULL
,	NULL
suggesting	NULL
that	NULL
SE	NULL
might	NULL
(	NULL
also	NULL
)	NULL
modulate	NULL
other	NULL
pathways	NULL
involved	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
cell	NULL
survival	NULL
and/or	NULL
apoptosis	NULL
.	NULL

DISCUSSION	NULL
In	NULL
the	NULL
present	NULL
study	NULL
,	NULL
we	NULL
provide	NULL
evidence	NULL
that	NULL
SE	NULL
induce	NULL
dynamic	NULL
and	NULL
selective	NULL
changes	NULL
in	NULL
the	NULL
expression	NULL
of	NULL
individual	NULL
IL-2R	NULL
chains	NULL
expressed	NULL
by	NULL
human	NULL
,	NULL
antigen-specific	NULL
,	NULL
MHC	NULL
class	NULL
:	NULL
Fig	NULL
.	NULL

5	NULL
.	NULL

SE-induced	NULL
apoptosis	NULL
30	NULL
-	NULL
can	NULL
not	NULL
be	NULL
reversed	NULL
by	NULL
exogenous	NULL
(	NULL
IL-2	NULL
.	NULL

Cells	NULL
were	NULL
incubated	NULL
with	NULL
(	NULL
@	NULL
)	NULL
20	NULL
or	NULL
without	NULL
(	NULL
O0	NULL
)	NULL
SE	NULL
for	NULL
4	NULL
hr	NULL
and	NULL
washed	NULL
extensively	NULL
prior	NULL
to	NULL
24	NULL
or	NULL
48	NULL
10	NULL
/\c	NULL
hr	NULL
of	NULL
culture	NULL
with	NULL
IL-2	NULL
at	NULL
200	NULL
©	NULL
units/ml	NULL
at	NULL
37°C	NULL
in	NULL
a	NULL
humidified	NULL
10	NULL
atmosphere	NULL
containing	NULL
5	NULL
%	NULL
CO	NULL
:	NULL
_	NULL
followed	NULL
by	NULL
flow	NULL
cytometric	NULL
exam	NULL
apoptotic	NULL
cells	NULL
(	NULL
%	NULL
)	NULL
0	NULL
24	NULL
48	NULL
_	NULL
ination	NULL
for	NULL
apoptosis	NULL
in	NULL
CD4+*	NULL
T-IL-2	NULL
culture	NULL
cell	NULL
lines	NULL
;	NULL
10*	NULL
events	NULL
were	NULL
analyzed	NULL
(	NULL
hours	NULL
)	NULL
for	NULL
each	NULL
observation	NULL
point	NULL
shown	NULL
.	NULL

II-positive	NULL
CD4*	NULL
T-cell	NULL
lines	NULL
.	NULL

SE-induced	NULL
changes	NULL
in	NULL
the	NULL
composition	NULL
of	NULL
IL-2Rs	NULL
were	NULL
accompanied	NULL
by	NULL
profound	NULL
changes	NULL
in	NULL
ligand-induced	NULL
receptor	NULL
signaling	NULL
.	NULL

Thus	NULL
,	NULL
IL-2-induced	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
Jak3	NULL
and	NULL
Stat3	NULL
and	NULL
Stats	NULL
transcription	NULL
factors	NULL
was	NULL
profoundly	NULL
inhibited	NULL
after	NULL
4	NULL
hr	NULL
of	NULL
exposure	NULL
to	NULL
SE	NULL
.	NULL

Since	NULL
both	NULL
the	NULL
B	NULL
and	NULL
the	NULL
y	NULL
chains	NULL
bind	NULL
Jak3	NULL
upon	NULL
IL-2	NULL
ligation	NULL
(	NULL
29	NULL
)	NULL
,	NULL
the	NULL
influence	NULL
of	NULL
an	NULL
altered	NULL
IL-2R	NULL
composition	NULL
on	NULL
receptor	NULL
signaling	NULL
was	NULL
difficult	NULL
to	NULL
predict	NULL
.	NULL

Interestingly	NULL
,	NULL
y	NULL
and	NULL
a	NULL
chains	NULL
can	NULL
not	NULL
associate	NULL
without	NULL
the	NULL
B	NULL
chain	NULL
being	NULL
involved	NULL
,	NULL
indicating	NULL
that	NULL
the	NULL
IL-2R	NULL
B	NULL
chain	NULL
is	NULL
a	NULL
critical	NULL
regulator	NULL
of	NULL
the	NULL
response	NULL
(	NULL
42	NULL
)	NULL
.	NULL

Our	NULL
observation	NULL
that	NULL
ligand-induced	NULL
Jak3	NULL
phos-phorylation	NULL
,	NULL
despite	NULL
an	NULL
upregulation	NULL
of	NULL
IL-2Ry	NULL
,	NULL
was	NULL
profoundly	NULL
inhibited	NULL
by	NULL
a	NULL
50	NULL
%	NULL
reduction	NULL
in	NULL
the	NULL
expression	NULL
of	NULL
supports	NULL
the	NULL
assumption	NULL
that	NULL
the	NULL
IL-2R	NULL
$	NULL
8	NULL
chain	NULL
plays	NULL
a	NULL
key	NULL
role	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
IL-2R	NULL
signal	NULL
transduction	NULL
.	NULL

After	NULL
16	NULL
hr	NULL
of	NULL
exposure	NULL
to	NULL
SE	NULL
,	NULL
however	NULL
,	NULL
ligand-induced	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
Jak3	NULL
and	NULL
Stat	NULL
proteins	NULL
was	NULL
partly	NULL
normalized	NULL
despite	NULL
a	NULL
continued	NULL
low	NULL
IL-2RB	NULL
expression	NULL
,	NULL
suggesting	NULL
that	NULL
other	NULL
factors	NULL
may	NULL
also	NULL
influence	NULL
receptor	NULL
signaling	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
up-regulation	NULL
of	NULL
IL-2Ra	NULL
expression	NULL
after	NULL
16	NULL
hr	NULL
of	NULL
SE	NULL
treatment	NULL
might	NULL
indirectly	NULL
enhance	NULL
signaling	NULL
through	NULL
the	NULL
remaining	NULL
and	NULL
-y	NULL
complexes	NULL
.	NULL

An	NULL
alternative	NULL
,	NULL
but	NULL
not	NULL
mutually	NULL
exclusive	NULL
explanation	NULL
might	NULL
be	NULL
that	NULL
exposure	NULL
to	NULL
SE	NULL
induced	NULL
changes	NULL
in	NULL
additional	NULL
intracellular	NULL
signaling	NULL
pathways	NULL
.	NULL

In	NULL
support	NULL
of	NULL
this	NULL
possibility	NULL
,	NULL
profound	NULL
signaling	NULL
defects	NULL
have	NULL
been	NULL
described	NULL
in	NULL
T	NULL
cells	NULL
rendered	NULL
anergic	NULL
following	NULL
stimulation	NULL
through	NULL
the	NULL
TCR-CD3	NULL
complex	NULL
(	NULL
20-24	NULL
)	NULL
.	NULL

Since	NULL
TCR-CD3	NULL
mAb	NULL
and	NULL
SE	NULL
did	NULL
not	NULL
induce	NULL
activation	NULL
of	NULL
Jak3	NULL
and	NULL
Stat	NULL
proteins	NULL
per	NULL
se	NULL
(	NULL
ref	NULL
.	NULL

31	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
JAK/Stat	NULL
inhibition	NULL
was	NULL
not	NULL
simply	NULL
a	NULL
matter	NULL
of	NULL
substrate	NULL
competition	NULL
or	NULL
depletion	NULL
.	NULL

Anergized	NULL
murine	NULL
T	NULL
cells	NULL
have	NULL
an	NULL
altered	NULL
expression	NULL
of	NULL
p56	NULL
``	NULL
and	NULL
p59	NULL
%	NULL
Y	NULL
``	NULL
and	NULL
exhibit	NULL
altered	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
additional	NULL
substrates	NULL
following	NULL
antigen	NULL
receptor	NULL
stimulation	NULL
(	NULL
23	NULL
,	NULL
24	NULL
,	NULL
46	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
changes	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
transcription	NULL
factors	NULL
such	NULL
as	NULL
AP-1	NULL
,	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
and	NULL
NF-AT	NULL
have	NULL
been	NULL
observed	NULL
in	NULL
anergic	NULL
cells	NULL
(	NULL
21	NULL
,	NULL
47	NULL
)	NULL
.	NULL

Since	NULL
some	NULL
of	NULL
these	NULL
kinases	NULL
and	NULL
transcription	NULL
factors-	NULL
e.g	NULL
.	NULL

,	NULL
p56	NULL
``	NULL
*	NULL
and	NULL
NF-	NULL
«	NULL
B-are	NULL
also	NULL
involved	NULL
in	NULL
IL-2R	NULL
signaling	NULL
and	NULL
proliferation	NULL
,	NULL
it	NULL
is	NULL
possible	NULL
that	NULL
an	NULL
interference	NULL
by	NULL
SE	NULL
with	NULL
these	NULL
signaling	NULL
molecules	NULL
might	NULL
play	NULL
a	NULL
role	NULL
in	NULL
SE-induced	NULL
IL-2	NULL
nonresponsiveness	NULL
.	NULL

Interestingly	NULL
,	NULL
proliferative	NULL
responses	NULL
to	NULL
IL-2	NULL
remained	NULL
profoundly	NULL
inhibited	NULL
after	NULL
16	NULL
hr	NULL
of	NULL
SE	NULL
treatment	NULL
.	NULL

Yet	NULL
,	NULL
IL-2R	NULL
ligation	NULL
induced	NULL
subnormal	NULL
but	NULL
significant	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
Jak3	NULL
and	NULL
Stat	NULL
proteins	NULL
.	NULL

Taken	NULL
together	NULL
these	NULL
observations	NULL
suggest	NULL
that	NULL
Jak3/Stat	NULL
activation	NULL
may	NULL
not	NULL
be	NULL
sufficient	NULL
for	NULL
receptor-induced	NULL
proliferation	NULL
.	NULL

This	NULL
conclusion	NULL
was	NULL
supported	NULL
by	NULL
a	NULL
recent	NULL
report	NULL
from	NULL
Fujii	NULL
et	NULL
al	NULL
.	NULL

(	NULL
48	NULL
)	NULL
that	NULL
deletions	NULL
in	NULL
the	NULL
IL-2R	NULL
that	NULL
blocked	NULL
ligand-induced	NULL
Stat5	NULL
phosphorylation	NULL
did	NULL
not	NULL
block	NULL
IL-2-driven	NULL
growth	NULL
.	NULL

It	NULL
remains	NULL
to	NULL
be	NULL
seen	NULL
how	NULL
crosstalk	NULL
takes	NULL
place	NULL
between	NULL
SE	NULL
receptors	NULL
and	NULL
IL-2	NULL
receptors	NULL
and	NULL
their	NULL
associated	NULL
signaling	NULL
molecules	NULL
.	NULL

Herbimycin	NULL
A	NULL
,	NULL
an	NULL
inhibitor	NULL
of	NULL
tyrosine	NULL
kinases	NULL
,	NULL
Immunology	NULL
:	NULL
Nielsen	NULL
et	NULL
al	NULL
.	NULL

could	NULL
only	NULL
partly	NULL
inhibit	NULL
SE-induced	NULL
down-regulation	NULL
of	NULL
IL2RB	NULL
chains	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
tyrosine	NULL
kinase-dependent	NULL
and	NULL
-independent	NULL
receptor	NULL
crosstalk	NULL
might	NULL
play	NULL
a	NULL
role	NULL
in	NULL
SE-induced	NULL
IL-2R	NULL
modulation	NULL
.	NULL

Since	NULL
cyclosporin	NULL
A	NULL
was	NULL
reported	NULL
to	NULL
inhibit	NULL
SE-induced	NULL
apoptosis	NULL
in	NULL
human	NULL
CD4*	NULL
T-cell	NULL
lines	NULL
(	NULL
12	NULL
)	NULL
,	NULL
it	NULL
is	NULL
likely	NULL
that	NULL
the	NULL
calcineurin-calmodulin	NULL
pathway	NULL
may	NULL
participate	NULL
in	NULL
crosstalk	NULL
between	NULL
SE	NULL
and	NULL
IL-2	NULL
receptor-associated	NULL
signaling	NULL
pathways	NULL
.	NULL

MHC	NULL
class	NULL
II-positive	NULL
T	NULL
cells	NULL
bind	NULL
SE	NULL
with	NULL
high	NULL
affinity	NULL
,	NULL
whereas	NULL
resting	NULL
class	NULL
II-negative	NULL
T	NULL
cells	NULL
do	NULL
not	NULL
;	NULL
therefore	NULL
,	NULL
MHC	NULL
class	NULL
II	NULL
molecules	NULL
are	NULL
believed	NULL
to	NULL
be	NULL
the	NULL
principal	NULL
SE	NULL
receptors	NULL
on	NULL
T	NULL
cells	NULL
.	NULL

However	NULL
,	NULL
both	NULL
MHC	NULL
class	NULL
II	NULL
and	NULL
TCR/	NULL
CD3	NULL
molecules	NULL
play	NULL
a	NULL
critical	NULL
role	NULL
in	NULL
the	NULL
early	NULL
signaling	NULL
events	NULL
after	NULL
exposure	NULL
of	NULL
T-cell	NULL
lines	NULL
to	NULL
SE	NULL
(	NULL
9	NULL
)	NULL
.	NULL

Indeed	NULL
,	NULL
circumstantial	NULL
evidence	NULL
suggests	NULL
that	NULL
bridging	NULL
of	NULL
MHC	NULL
class	NULL
II	NULL
and	NULL
TCR/	NULL
CD3	NULL
molecules	NULL
in	NULL
cis	NULL
by	NULL
SE	NULL
or	NULL
mAb	NULL
generates	NULL
enhanced	NULL
early	NULL
signaling	NULL
events	NULL
as	NULL
compared	NULL
with	NULL
separate	NULL
ligation	NULL
of	NULL
MHC	NULL
and	NULL
TCR/CD3	NULL
molecules	NULL
(	NULL
9	NULL
,	NULL
49	NULL
)	NULL
.	NULL

These	NULL
observations	NULL
might	NULL
explain	NULL
why	NULL
SE	NULL
are	NULL
much	NULL
more	NULL
potent	NULL
inducers	NULL
of	NULL
IL-2	NULL
nonresponsiveness	NULL
and	NULL
apoptosis	NULL
than	NULL
are	NULL
anti-TCR/CD3	NULL
mAbs	NULL
(	NULL
unpublished	NULL
observations	NULL
)	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
our	NULL
results	NULL
show	NULL
that	NULL
SE	NULL
modulate	NULL
the	NULL
expression	NULL
and	NULL
composition	NULL
of	NULL
IL-2R	NULL
and	NULL
interfere	NULL
with	NULL
ligand-induced	NULL
activation	NULL
of	NULL
the	NULL
JAK/Stat	NULL
signal	NULL
pathway	NULL
.	NULL

This	NULL
ability	NULL
of	NULL
SE	NULL
to	NULL
down-regulate	NULL
cytokine	NULL
receptor	NULL
signaling	NULL
and	NULL
proliferation	NULL
and	NULL
to	NULL
induce	NULL
apoptosis	NULL
has	NULL
potential	NULL
implications	NULL
in	NULL
the	NULL
pathogenesis	NULL
in	NULL
AIDS	NULL
.	NULL

Human	NULL
immunodeficiency	NULL
virus	NULL
(	NULL
HIV	NULL
)	NULL
-infected	NULL
individuals	NULL
are	NULL
thus	NULL
prone	NULL
to	NULL
harbor	NULL
infections	NULL
,	NULL
including	NULL
those	NULL
capable	NULL
of	NULL
producing	NULL
SE	NULL
.	NULL

Exposure	NULL
of	NULL
activated	NULL
,	NULL
antigen-specific	NULL
,	NULL
MHC	NULL
class	NULL
II-positive	NULL
T	NULL
cells	NULL
to	NULL
SE	NULL
may	NULL
induce	NULL
nonresponsiveness	NULL
and	NULL
apoptosis	NULL
in	NULL
HIV-infected	NULL
individuals	NULL
and	NULL
thus	NULL
contribute	NULL
to	NULL
and	NULL
aggravate	NULL
the	NULL
immunodeficiency	NULL
and	NULL
depletion	NULL
of	NULL
CD4*	NULL
T	NULL
cells	NULL
associated	NULL
with	NULL
AIDS	NULL
.	NULL

We	NULL
thank	NULL
Mr.	NULL
K.	NULL
Sugamura	NULL
,	NULL
Tohoku	NULL
University	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
Sendai	NULL
,	NULL
Japan	NULL
,	NULL
for	NULL
kindly	NULL
providing	NULL
the	NULL
IL-2R	NULL
y	NULL
antibody	NULL
(	NULL
TUGh4	NULL
)	NULL
.	NULL

We	NULL
wish	NULL
to	NULL
thank	NULL
Gitte	NULL
Kglander	NULL
for	NULL
technical	NULL
assistance	NULL
,	NULL
and	NULL
Jan	NULL
Pravsgaard	NULL
Christensen	NULL
for	NULL
help	NULL
in	NULL
making	NULL
the	NULL
FACS-illustrations	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
and	NULL
Anne-Mette	NULL
Borre	NULL
Carlsen	NULL
for	NULL
making	NULL
other	NULL
illustrations	NULL
(	NULL
Figs	NULL
.	NULL

1	NULL
and	NULL
5	NULL
)	NULL
.	NULL

This	NULL
research	NULL
was	NULL
supported	NULL
by	NULL
the	NULL
Beckett	NULL
Foundation	NULL
,	NULL
the	NULL
Novo	NULL
Nordic	NULL
Foundation	NULL
,	NULL
the	NULL
Danish	NULL
Biotechnological	NULL
Center	NULL
for	NULL
Signal	NULL
Peptide	NULL
Research	NULL
,	NULL
the	NULL
Danish	NULL
Medical	NULL
Associations	NULL
Research	NULL
Fund	NULL
(	NULL
LaegeforeningensForskningsfond	NULL
)	NULL
,	NULL
Kong	NULL
Christian	NULL
Fund	NULL
,	NULL
Kgl	NULL
.	NULL

Hofbundtmager	NULL
Aage	NULL
Bangs	NULL
Fund	NULL
,	NULL
the	NULL
Danish	NULL
Natural	NULL
Science	NULL
Research	NULL
Council	NULL
,	NULL
and	NULL
the	NULL
Danish	NULL
Medical	NULL
Research	NULL
Council	NULL
(	NULL
research	NULL
fellowship	NULL
for	NULL
M.N	NULL
.	NULL
)	NULL

.	NULL

1	NULL
.	NULL

Kotzin	NULL
,	NULL
B.	NULL
L.	NULL
,	NULL
Leung	NULL
,	NULL
D.	NULL
Y.	NULL
M.	NULL
,	NULL
Kappler	NULL
,	NULL
J	NULL
.	NULL

&	NULL
Marrack	NULL
,	NULL
P.	NULL
(	NULL
1993	NULL
)	NULL
Adv	NULL
.	NULL

Immunol	NULL
.	NULL

54	NULL
,	NULL
99-146	NULL
.	NULL

2	NULL
.	NULL

-	NULL
Langford	NULL
,	NULL
M.	NULL
P.	NULL
,	NULL
Stanton	NULL
,	NULL
G.	NULL
J	NULL
.	NULL

&	NULL
Johnson	NULL
,	NULL
H.	NULL
M.	NULL
(	NULL
1978	NULL
)	NULL
Infect	NULL
.	NULL

Immun	NULL
.	NULL

22	NULL
,	NULL
62-68	NULL
.	NULL

3	NULL
.	NULL

Carlsson	NULL
,	NULL
R.	NULL
&	NULL
Sjogren	NULL
,	NULL
H.	NULL
O	NULL
.	NULL

(	NULL
1985	NULL
)	NULL
Cell	NULL
.	NULL

Immunol	NULL
.	NULL

96	NULL
,	NULL
175-183	NULL
.	NULL

4	NULL
.	NULL

Carlsson	NULL
,	NULL
R.	NULL
,	NULL
Fisher	NULL
,	NULL
H.	NULL
&	NULL
Sjogren	NULL
,	NULL
H.	NULL
O	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

140	NULL
,	NULL
2484-2488	NULL
.	NULL

5	NULL
.	NULL

Fraser	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
Newton	NULL
,	NULL
M.	NULL
E.	NULL
&	NULL
Weiss	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

175	NULL
,	NULL
1131-1134	NULL
.	NULL

6	NULL
.	NULL

Kappler	NULL
,	NULL
J.	NULL
,	NULL
Kotzin	NULL
,	NULL
B.	NULL
,	NULL
Herron	NULL
,	NULL
L.	NULL
,	NULL
Geifanf	NULL
,	NULL
E.	NULL
,	NULL
Bigler	NULL
,	NULL
R.	NULL
,	NULL
Boylston	NULL
,	NULL
A.	NULL
,	NULL
Carrel	NULL
,	NULL
S.	NULL
,	NULL
Posnett	NULL
,	NULL
D.	NULL
,	NULL
Choi	NULL
,	NULL
Y	NULL
.	NULL

&	NULL
Marrack	NULL
,	NULL
P.	NULL
(	NULL
1989	NULL
)	NULL
Science	NULL
244	NULL
,	NULL
811-813	NULL
.	NULL

7	NULL
.	NULL

Morio	NULL
,	NULL
T.	NULL
,	NULL
Geha	NULL
,	NULL
R.-S.	NULL
&	NULL
Chatila	NULL
,	NULL
T.-A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

24	NULL
,	NULL
651-658	NULL
.	NULL

8	NULL
.	NULL

Chatila	NULL
,	NULL
T.	NULL
,	NULL
Wood	NULL
,	NULL
N.	NULL
,	NULL
Parsonnet	NULL
,	NULL
J	NULL
.	NULL

&	NULL
Geha	NULL
,	NULL
R.-S.	NULL
(	NULL
1988	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

140	NULL
,	NULL
1250-1255	NULL
.	NULL

9	NULL
.	NULL

Kanner	NULL
,	NULL
S.-B	NULL
.	NULL

,	NULL
Odum	NULL
,	NULL
N.	NULL
,	NULL
Grosmaire	NULL
,	NULL
L.	NULL
,	NULL
Masewicz	NULL
,	NULL
$	NULL
.	NULL

,	NULL
Svejgaard	NULL
,	NULL
A	NULL
.	NULL

&	NULL
Ledbetter	NULL
,	NULL
J.-A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

149	NULL
,	NULL
3482-3488	NULL
.	NULL

10	NULL
.	NULL

Kawabe	NULL
,	NULL
Y	NULL
.	NULL

&	NULL
Ochi	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

172	NULL
,	NULL
1065-1070	NULL
.	NULL

11	NULL
.	NULL

Kawabe	NULL
,	NULL
Y	NULL
.	NULL

&	NULL
Ochi	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
349	NULL
,	NULL
245-248	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
92	NULL
(	NULL
1995	NULL
)	NULL
-	NULL
10999	NULL
Damle	NULL
,	NULL
N.-K.	NULL
,	NULL
Leytze	NULL
,	NULL
G.	NULL
,	NULL
Klussman	NULL
,	NULL
K.	NULL
&	NULL
Ledbetter	NULL
,	NULL
J.-A	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

23	NULL
,	NULL
1513-1522	NULL
.	NULL

O'Hehir	NULL
,	NULL
R.-E.	NULL
&	NULL
Lamb	NULL
,	NULL
J.-R.	NULL
(	NULL
1990	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
87	NULL
,	NULL
8884-8888	NULL
.	NULL

White	NULL
,	NULL
J.	NULL
,	NULL
Herman	NULL
,	NULL
A.	NULL
,	NULL
Pullen	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
Kubo	NULL
,	NULL
R.	NULL
,	NULL
Kappler	NULL
,	NULL
J.	NULL
W.	NULL
&	NULL
Marrack	NULL
,	NULL
P.	NULL
(	NULL
1989	NULL
)	NULL
Cell	NULL
56	NULL
,	NULL
27-35	NULL
.	NULL

Rammensee	NULL
,	NULL
H.-G.	NULL
,	NULL
Kroschewski	NULL
,	NULL
R.	NULL
&	NULL
Frangoulis	NULL
,	NULL
B	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
339	NULL
,	NULL
541-544	NULL
.	NULL

Hewitt	NULL
,	NULL
C.-R.	NULL
,	NULL
Lamb	NULL
,	NULL
J.-R.	NULL
,	NULL
Hayball	NULL
,	NULL
J.	NULL
,	NULL
Hill	NULL
,	NULL
M.	NULL
,	NULL
Owen	NULL
,	NULL
M.-J	NULL
.	NULL

&	NULL
O'Hehir	NULL
,	NULL
R.-E.	NULL
(	NULL
1992	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

175	NULL
,	NULL
1493-1499	NULL
.	NULL

Lando	NULL
,	NULL
P.	NULL
A.	NULL
,	NULL
Dohisten	NULL
,	NULL
M.	NULL
,	NULL
Hedlund	NULL
,	NULL
G.	NULL
,	NULL
Brodin	NULL
,	NULL
T.	NULL
,	NULL
Sansom	NULL
,	NULL
D.	NULL
&	NULL
Kalland	NULL
,	NULL
T.	NULL
(	NULL
1993	NULL
)	NULL
Immunology	NULL
80	NULL
,	NULL
236-241	NULL
.	NULL

Fisher	NULL
,	NULL
H.	NULL
,	NULL
Gjorloff	NULL
,	NULL
A.	NULL
,	NULL
Hedlund	NULL
,	NULL
G.	NULL
,	NULL
Hedman	NULL
,	NULL
H.	NULL
,	NULL
Lundgren	NULL
,	NULL
E.	NULL
,	NULL
Kalland	NULL
,	NULL
T.	NULL
,	NULL
Sjogren	NULL
,	NULL
H.	NULL
O	NULL
.	NULL

&	NULL
Dohisten	NULL
,	NULL
M.	NULL
(	NULL
1992	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

148	NULL
,	NULL
1993-1998	NULL
.	NULL

Van	NULL
Seventer	NULL
,	NULL
G.	NULL
A.	NULL
,	NULL
Newman	NULL
,	NULL
W.	NULL
,	NULL
Shimizu	NULL
,	NULL
Y.	NULL
,	NULL
Nutman	NULL
,	NULL
T.	NULL
B.	NULL
,	NULL
Tanaka	NULL
,	NULL
Y.	NULL
,	NULL
Horgan	NULL
,	NULL
K.	NULL
J.	NULL
,	NULL
Gopal	NULL
,	NULL
T.	NULL
V.	NULL
,	NULL
Ennis	NULL
,	NULL
E.	NULL
,	NULL
O'Sullivan	NULL
,	NULL
D.	NULL
,	NULL
Grey	NULL
,	NULL
H.	NULL
&	NULL
Shaw	NULL
,	NULL
S.	NULL
(	NULL
1991	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

174	NULL
,	NULL
901-913	NULL
.	NULL

Blackman	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
Finkel	NULL
,	NULL
T.	NULL
H.	NULL
,	NULL
Kappler	NULL
,	NULL
J.	NULL
,	NULL
Cambier	NULL
,	NULL
J	NULL
.	NULL

&	NULL
Marrack	NULL
,	NULL
P.	NULL
(	NULL
1991	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
88	NULL
,	NULL
6682-6686	NULL
.	NULL

Go	NULL
,	NULL
C.	NULL
&	NULL
Miller	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

175	NULL
,	NULL
1327-1336	NULL
.	NULL

Gajewski	NULL
,	NULL
T.	NULL
F.	NULL
,	NULL
Qian	NULL
,	NULL
D.	NULL
,	NULL
Fields	NULL
,	NULL
P.	NULL
&	NULL
Fitch	NULL
,	NULL
F.	NULL
W.	NULL
(	NULL
1994	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
91	NULL
,	NULL
38-42	NULL
.	NULL

Quill	NULL
,	NULL
H.	NULL
,	NULL
Riley	NULL
,	NULL
M.-P.	NULL
,	NULL
Cho	NULL
,	NULL
E.-A	NULL
.	NULL

,	NULL
Casnellie	NULL
,	NULL
J.-E.	NULL
,	NULL
Reed	NULL
,	NULL
J.-C.	NULL
&	NULL
Torigoe	NULL
,	NULL
T.	NULL
(	NULL
1992	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

149	NULL
,	NULL
2887-2893	NULL
.	NULL

Bhandooia	NULL
,	NULL
A.	NULL
,	NULL
Cho	NULL
,	NULL
E.-A	NULL
.	NULL

,	NULL
Yui	NULL
,	NULL
K.	NULL
,	NULL
Saragovi	NULL
,	NULL
U.	NULL
,	NULL
Greene	NULL
,	NULL
M.-I	NULL
.	NULL

&	NULL
Quill	NULL
,	NULL
H.	NULL
(	NULL
1993	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

151	NULL
,	NULL
2355-2367	NULL
.	NULL

Hatakeyama	NULL
,	NULL
M.	NULL
,	NULL
Kono	NULL
,	NULL
T.	NULL
,	NULL
Kobayshi	NULL
,	NULL
N.	NULL
,	NULL
Kawahara	NULL
,	NULL
A.	NULL
,	NULL
Levin	NULL
,	NULL
S.-D.	NULL
,	NULL
Perlmutter	NULL
,	NULL
R.	NULL
M.	NULL
&	NULL
Taniguchi	NULL
,	NULL
T.	NULL
(	NULL
1991	NULL
)	NULL
Science	NULL
252	NULL
,	NULL
1523-1528	NULL
.	NULL

Johnston	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Kawamura	NULL
,	NULL
M.	NULL
,	NULL
Kirken	NULL
,	NULL
R.	NULL
A.	NULL
,	NULL
Chen	NULL
,	NULL
Y.	NULL
,	NULL
Blake	NULL
,	NULL
T.	NULL
B.	NULL
,	NULL
Shibya	NULL
,	NULL
K.	NULL
,	NULL
Ortaldo	NULL
,	NULL
J.	NULL
R.	NULL
,	NULL
Mcviar	NULL
,	NULL
D.	NULL
W.	NULL
&	NULL
O'Shea	NULL
,	NULL
J.	NULL
J	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
370	NULL
,	NULL
151-153	NULL
.	NULL

Witthuhn	NULL
,	NULL
B	NULL
.	NULL

A.	NULL
,	NULL
Silvennoinen	NULL
,	NULL
O.	NULL
,	NULL
Miura	NULL
,	NULL
O.	NULL
,	NULL
Lai	NULL
,	NULL
K.	NULL
S.	NULL
,	NULL
Cwik	NULL
,	NULL
C.	NULL
,	NULL
Liu	NULL
,	NULL
E.	NULL
T.	NULL
&	NULL
Thle	NULL
,	NULL
J.	NULL
N.	NULL
(	NULL
1994	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
370	NULL
,	NULL
153-157	NULL
.	NULL

Maslinski	NULL
,	NULL
W.	NULL
,	NULL
Remillard	NULL
,	NULL
B.	NULL
,	NULL
Tsudo	NULL
,	NULL
M.	NULL
&	NULL
Strom	NULL
,	NULL
T.	NULL
B	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

267	NULL
,	NULL
15281-15284	NULL
.	NULL

Miyazaki	NULL
,	NULL
T.	NULL
,	NULL
Kawahara	NULL
,	NULL
A.	NULL
,	NULL
Fujii	NULL
,	NULL
H.	NULL
,	NULL
Nakagawa	NULL
,	NULL
T.	NULL
,	NULL
Minami	NULL
,	NULL
Y.	NULL
,	NULL
Liu	NULL
,	NULL
Z.	NULL
,	NULL
Oishi	NULL
,	NULL
I.	NULL
,	NULL
Silvennoinen	NULL
,	NULL
O.	NULL
,	NULL
Witthuhn	NULL
,	NULL
B.-A	NULL
.	NULL

,	NULL
Thie	NULL
,	NULL
J.-N.	NULL
&	NULL
Tadatsugu	NULL
,	NULL
T.	NULL
(	NULL
1994	NULL
)	NULL
Science	NULL
266	NULL
,	NULL
1045-1047	NULL
.	NULL

Nielsen	NULL
,	NULL
M.	NULL
,	NULL
Svejgaard	NULL
,	NULL
A.	NULL
,	NULL
Skov	NULL
,	NULL
S.	NULL
&	NULL
Odum	NULL
,	NULL
N.	NULL
(	NULL
1994	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

24	NULL
,	NULL
3082-3086	NULL
.	NULL

Beadling	NULL
,	NULL
C.	NULL
,	NULL
Guschin	NULL
,	NULL
D.	NULL
,	NULL
Witthuhn	NULL
,	NULL
B.-A	NULL
.	NULL

,	NULL
Ziemiecki	NULL
,	NULL
A.	NULL
,	NULL
Ihle	NULL
,	NULL
J.-N.	NULL
,	NULL
Kerr	NULL
,	NULL
L.-M.	NULL
&	NULL
Cantrell	NULL
,	NULL
D.-A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

13	NULL
,	NULL
5605-5615	NULL
.	NULL

Lin	NULL
,	NULL
J.-X	NULL
.	NULL

,	NULL
Migone	NULL
,	NULL
T.-S.	NULL
,	NULL
Tsang	NULL
,	NULL
M.	NULL
,	NULL
Friedmann	NULL
,	NULL
M.	NULL
,	NULL
Weatherbee	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Zhou	NULL
,	NULL
L.	NULL
,	NULL
Yamauchi	NULL
,	NULL
A.	NULL
,	NULL
Bloom	NULL
,	NULL
E.	NULL
T.	NULL
,	NULL
Mictz	NULL
,	NULL
J.	NULL
,	NULL
John	NULL
,	NULL
S.	NULL
&	NULL
Leonard	NULL
,	NULL
W.	NULL
J	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Immunity	NULL
2	NULL
,	NULL
331-339	NULL
.	NULL

Hou	NULL
,	NULL
J.	NULL
,	NULL
Schindler	NULL
,	NULL
U.	NULL
,	NULL
Henzel	NULL
,	NULL
W.	NULL
J.	NULL
,	NULL
Wong	NULL
,	NULL
S.	NULL
C.	NULL
&	NULL
McKnight	NULL
,	NULL
S.	NULL
L.	NULL
(	NULL
1995	NULL
)	NULL
Immunity	NULL
2	NULL
,	NULL
321-329	NULL
.	NULL

Ishii	NULL
,	NULL
N.	NULL
,	NULL
Takeshita	NULL
,	NULL
T.	NULL
,	NULL
Kimura	NULL
,	NULL
Y.	NULL
,	NULL
Tada	NULL
,	NULL
K.	NULL
,	NULL
Kondo	NULL
,	NULL
M.	NULL
,	NULL
Nakamura	NULL
,	NULL
M.	NULL
&	NULL
Sugamura	NULL
,	NULL
K.	NULL
(	NULL
1994	NULL
)	NULL
Int	NULL
.	NULL

Immunol	NULL
.	NULL

6	NULL
,	NULL
1273-1277	NULL
.	NULL

Odum	NULL
,	NULL
N.	NULL
,	NULL
Hartzman	NULL
,	NULL
R.	NULL
,	NULL
Jakobsen	NULL
,	NULL
B.-K.	NULL
,	NULL
Morling	NULL
,	NULL
N.	NULL
,	NULL
Platz	NULL
,	NULL
P.	NULL
,	NULL
Robbins	NULL
,	NULL
F.-M.	NULL
,	NULL
Ryder	NULL
,	NULL
L-P.	NULL
&	NULL
Svejgaard	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1986	NULL
)	NULL
Tissue	NULL
Antigens	NULL
28	NULL
,	NULL
105-118	NULL
.	NULL

Nielsen	NULL
,	NULL
M.	NULL
,	NULL
Odum	NULL
,	NULL
N.	NULL
,	NULL
Bendtzen	NULL
,	NULL
K.	NULL
,	NULL
Ryder	NULL
,	NULL
L.-P.	NULL
,	NULL
Jakobsen	NULL
,	NULL
B.-K.	NULL
&	NULL
Svejgaard	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Exp	NULL
.	NULL

Clin	NULL
.	NULL

Immunogenet	NULL
.	NULL

11	NULL
,	NULL
23-32	NULL
.	NULL

Odum	NULL
,	NULL
N.	NULL
,	NULL
Ledbetter	NULL
,	NULL
J.-A	NULL
.	NULL

,	NULL
Martin	NULL
,	NULL
P.	NULL
,	NULL
Geraghty	NULL
,	NULL
D.	NULL
,	NULL
Tsu	NULL
,	NULL
T.	NULL
,	NULL
Hansen	NULL
,	NULL
J.-A	NULL
.	NULL

&	NULL
Gladstone	NULL
,	NULL
P.	NULL
(	NULL
1991	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

21	NULL
,	NULL
2121-2131	NULL
.	NULL

Vindeloev	NULL
,	NULL
L.-L.	NULL
,	NULL
Christensen	NULL
,	NULL
L.-J	NULL
.	NULL

&	NULL
Nissen	NULL
,	NULL
N.-I	NULL
.	NULL

(	NULL
1983	NULL
)	NULL
Cytometry	NULL
3	NULL
,	NULL
323-327	NULL
.	NULL

Moretta	NULL
,	NULL
A.	NULL
,	NULL
Acolla	NULL
,	NULL
R.	NULL
S.	NULL
&	NULL
Cerottini	NULL
,	NULL
J.-C.	NULL
(	NULL
1982	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

172	NULL
,	NULL
1513-1519	NULL
.	NULL

Odum	NULL
,	NULL
N.	NULL
,	NULL
Kanner	NULL
,	NULL
S.	NULL
B.	NULL
,	NULL
Ledbetter	NULL
,	NULL
J	NULL
.	NULL

A	NULL
.	NULL

&	NULL
Svejgaard	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

150	NULL
,	NULL
5289-5298	NULL
.	NULL

Chatila	NULL
,	NULL
T.	NULL
&	NULL
Geha	NULL
,	NULL
R.-S.	NULL
(	NULL
1993	NULL
)	NULL
Immunol	NULL
.	NULL

Rev	NULL
.	NULL

131	NULL
,	NULL
43-59	NULL
.	NULL

Nakari	NULL
,	NULL
T.	NULL
,	NULL
Robertson	NULL
,	NULL
M.-J	NULL
.	NULL

,	NULL
Streuli	NULL
,	NULL
M.	NULL
,	NULL
Wu	NULL
,	NULL
Z.	NULL
,	NULL
Ciardelli	NULL
,	NULL
T.-L.	NULL
,	NULL
Smith	NULL
,	NULL
K.-A	NULL
.	NULL

&	NULL
Ritz	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

180	NULL
,	NULL
241-251	NULL
.	NULL

Boussiotis	NULL
,	NULL
V.-A	NULL
.	NULL

,	NULL
Barber	NULL
,	NULL
D.-L.	NULL
,	NULL
Nakari	NULL
,	NULL
T.	NULL
,	NULL
Freeman	NULL
,	NULL
G.-J	NULL
.	NULL

,	NULL
Gribben	NULL
,	NULL
J.-G.	NULL
,	NULL
Bernstein	NULL
,	NULL
G.-M.	NULL
,	NULL
D'Andrea	NULL
,	NULL
A.-D.	NULL
,	NULL
Ritz	NULL
,	NULL
J	NULL
.	NULL

&	NULL
Nadler	NULL
,	NULL
L.-M.	NULL
(	NULL
1994	NULL
)	NULL
Science	NULL
266	NULL
,	NULL
1039-1042	NULL
.	NULL

Migita	NULL
,	NULL
K.	NULL
&	NULL
Ochi	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

24	NULL
,	NULL
2081-2086	NULL
.	NULL

Cohen	NULL
,	NULL
J.	NULL
J	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Adv	NULL
.	NULL

Immunol	NULL
.	NULL

50	NULL
,	NULL
55-83	NULL
.	NULL

Cho	NULL
,	NULL
E.-A	NULL
.	NULL

,	NULL
Riley	NULL
,	NULL
M.-P.	NULL
,	NULL
Sillman	NULL
,	NULL
A.	NULL
L.	NULL
&	NULL
Quill	NULL
,	NULL
H.	NULL
(	NULL
1993	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

151	NULL
,	NULL
20-28	NULL
.	NULL

Kang	NULL
,	NULL
S.	NULL
,	NULL
Beverly	NULL
,	NULL
B.	NULL
,	NULL
Tran	NULL
,	NULL
A.	NULL
,	NULL
Brorson	NULL
,	NULL
K.	NULL
,	NULL
Schwartz	NULL
,	NULL
R.-H.	NULL
&	NULL
Lenardo	NULL
,	NULL
M.-J	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Science	NULL
257	NULL
,	NULL
1134-1138	NULL
.	NULL

Fujii	NULL
,	NULL
H.	NULL
,	NULL
Nakagawa	NULL
,	NULL
Y.	NULL
,	NULL
Schindler	NULL
,	NULL
U.	NULL
,	NULL
Kawahara	NULL
,	NULL
A.	NULL
,	NULL
Mori	NULL
,	NULL
H.	NULL
,	NULL
Gouilleux	NULL
,	NULL
F.	NULL
,	NULL
Groner	NULL
,	NULL
B.	NULL
,	NULL
Ihle	NULL
,	NULL
J.	NULL
N.	NULL
,	NULL
Minami	NULL
,	NULL
Y.	NULL
,	NULL
Miyazaki	NULL
,	NULL
T.	NULL
&	NULL
Taniguchi	NULL
,	NULL
T.	NULL
(	NULL
1995	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
92	NULL
,	NULL
5482-5486	NULL
.	NULL

@	NULL
dum	NULL
,	NULL
N.	NULL
,	NULL
Martin	NULL
,	NULL
P.	NULL
J.	NULL
,	NULL
Schieven	NULL
,	NULL
G.	NULL
L.	NULL
,	NULL
Masewicz	NULL
,	NULL
S.	NULL
,	NULL
Hansen	NULL
,	NULL
J	NULL
.	NULL

A	NULL
.	NULL

&	NULL
Ledbetter	NULL
,	NULL
J	NULL
.	NULL

A	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Tissue	NULL
Antigens	NULL
38	NULL
,	NULL
72-77	NULL
.	NULL

